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ABBREVIATIONS 
2SC              S-(2-succinyl)-cysteine 
A adenine/alanine 
aa amino acid 
ALL              acute lymphoblastic leukemia 
AML             acute myeloid leukemia 
AP                 affinity purification 
C  cytosine/cysteine 
C-terminus  carboxy-terminus  
CCNC  cyclin C  
CDK8  cyclin-dependent kinase 8  
CDK19  cyclin-dependent kinase 19 
cDNA  complementary deoxyribonucleic acid  
CLL  chronic lymphocytic leukemia  
COL4A5  collagen type IV alpha 5  
COL4A6  collagen type IV alpha 6  
COSMIC  Catalogue of Somatic Mutations in 
Cancer 
CPG  cancer predisposing gene 
CTD  carboxy-terminal domain 
CUX1  cut-like homeobox 1  
D  aspartic acid  
del  deletion  
DNA  deoxyribonucleic acid 
E  glutamic acid  
ECM  extracellular matrix  
FF fresh frozen 
FFPE  formalin-fixed paraffin-embedded  
FH  fumarate hydratase  
G  guanine/glycine  
Gli3 glioma-associated oncogene family  
zinc finger 3 
H  histidine/histone 
HE            hematoxylin-eosin  
HIF1A      hypoxia-inducible factor 1 alpha 
HLRCC    hereditary leiomyomatosis and renal  
cell cancer  
HMGA1    high mobility group AT-hook 1  
HMGA2    high mobility group AT-hook 2 
HPV human papillomavirus 
ICGC        International Cancer Genome 
Consortium 
IF immunofluorescence 
IGHV       immunoglobulin heavy chain variable 
IHC immunohistochemistry 
ins             insertion 
K               lysine  
L 




lncRNA  long non-coding RNA 
LOH  loss of heterozygosity  
M methionine 
MED12 mediator complex subunit 12 
  
MED12L mediator complex subunit 12-like 
MED13         mediator complex subunit 13 
MED13L  mediator complex subunit 13-like  
MIM  Mendelian Inheritance in Man  
miRNA  micro-ribonucleic acid  
mRNA  messenger ribonucleic acid  
MS mass spectrometry 
MSI  microsatellite instability 
N asparagine 
NLS  nuclear localization signal  
NMD  nonsense mediated decay 
NOTCH1  Notch (Drosophila) homolog 1, 
translocation-associated  
NPC nuclear pore complex 
N-terminus  amino terminus 
OPA  opposite paired domain 
p  short arm of a chromosome  
P  proline 
PCP planar cell polarity 
PCR  polymerase chain reaction  
Pol II  RNA polymerase II  
q  long arm of a chromosome  
Q  glutamine 
R arginine 
RAD51B  RAD51 paralog B  
REST  RE1-silencing transcription factor  
RNA  ribonucleic acid  
S serine 
Shh  Sonic hedgehog 
STUMP smooth muscle tumor with uncertain 
malignant potential 
T  thymine/threonine 
T-ALL  T-cell acute lymphoblastic leukemia 
TCGA  The Cancer Genome Atlas 
TERT  telomerase reverse transcriptase 
TGF-β  transforming growth factor beta  
TGF-βR2  transforming growth factor beta 
receptor 2 
TMA  tissue microarray   
TP53  tumor protein 53  
TSG  tumor suppressor gene  
V  valine  
W tryptophan 
WB Western blotting 
WES  whole exome sequencing 
WGS  whole genome sequencing 
WHO the World Health Organization 
Wnt wingless-related integration site 
WT  wild type 
X X chromosome/stop 
XLID X-linked intellectual disability 
ZAP-70  70 kD zeta-associated protein 
 





Mediator complex subunit 12 (MED12), encoded by the mediator complex subunit 12 
gene on Xq13.1, is a component of a conserved Mediator complex and an important 
player in the regulation of general and gene-specific transcription. Mediator is a 
multiprotein complex required for ribonucleic acid (RNA) polymerase II-dependent 
transcription of most protein coding genes. MED12 composes the kinase module of 
the Mediator together with Mediator complex subunit 13 (MED13), Cyclin C (CCNC) 
and Cyclin-dependent kinase 8 or 19 (CDK8/19). With variable association to the 
Mediator core, it regulates the activity of the complex and also participates in scaffold 
formation and transcription elongation. Somatic MED12 mutations were implicated in 
human tumorigenesis for the first time when exome sequencing of uterine leiomyomas 
identified extremely frequent mutations in the gene. All the observed mutations were 
situated in an evolutionarily conserved area in exon 2 and the preceding intron-exon 
boundary. Mutations were missense changes affecting specific mutation hot spots and 
small in-frame insertions and deletions at the same genomic region. Uterine 
leiomyomas are benign smooth muscle tumors estimated to affect up to 77% of 
reproductive-age women. Despite their benign nature, clinically relevant lesions can 
cause a variety of symptoms, and, consequently, uterine leiomyomas are the most 
common indication for hysterectomy. Most tumors are sporadic, but uterine 
leiomyomas are also a feature of hereditary leiomyomatosis and renal cell cancer 
syndrome (HLRCC), where biallelic inactivation of fumarate hydratase (FH) is 
driving the tumorigenesis. 
 
The overall aim of this thesis project was to take forward the recent finding of MED12 
as a novel driver gene in myomagenesis and to analyze its role in other tumor types. 
MED12 exon 2 mutation screening of 1158 samples of various tumor types, both 
benign and malignant, identified mutations recurrently in uterine leiomyosarcoma 
(7%) and rarely in colorectal cancer (0.5%). These findings demonstrate that MED12 
exon 2 mutations are not restricted to benign tumors and suggest the possibility that 
some leiomyosarcomas develop via benign leiomyoma precursors. A sample series 
representing all the tumor types where MED12 exon 2 mutations has previously been 
reported and including only exon 2 mutation-negative tumors were screened for 
exon 1 mutations. Small in-frame deletions were observed only in conventional 
uterine leiomyomas with a frequency of 6%, further emphasizing the role of MED12 
in leiomyomagenesis. Gene expression analysis, immunoprecipitations, and kinase 
activity assays demonstrated that mutations in exon 1 lead to similar global expression 
profiles and mechanistic effects, including diminished interaction between MED12 
and Cyclin C-CDK8/19 and decreased Mediator-associated kinase activity, as 
previously observed with exon 2 mutations.  
 
Immunohistochemical analysis of the FH status and MED12 exon 1/2 mutation 
screening confirmed that biallelic FH inactivation and MED12 mutations are mutually 
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exclusive, both within HLRCC syndrome-associated and sporadic uterine 
leiomyomas. Based on gene expression profiling, FH-deficient tumors clustered 
together, whereas HLRCC patients’ MED12 mutation-positive tumors clustered with 
their sporadic counterparts. These results show that there are at least two distinct 
molecular mechanisms behind the development of uterine leiomyomas in HLRCC 
patients: biallelic FH inactivation and somatic MED12 mutations. 
 
A systematic database search utilizing the COSMIC (Catalogue of Somatic Mutations 
in Cancer) database identified few MED12 mutations affecting the myoma-linked 
mutation hotspots also in chronic lymphocytic leukemia (CLL), the most common 
form of leukemia in adults. Mutation screening of more than 700 CLL samples 
revealed MED12 exon 1 and 2 mutations with a frequency of 5% in CLL, making it 
the first extrauterine cancer where these specific mutations have been observed at a 
significant frequency. Analysis of molecular and clinical data of 260 patients revealed 
that positive MED12 mutation status associated with unmutated status of 
immunoglobulin heavy chain variable (IGHV) genes and elevated expression of 70 kD 
zeta-associated protein (ZAP-70), both of which are well-characterized markers of 
poor prognosis in CLL. 
 
Functional analysis of the first nonsense mutation identified at the amino (N) terminus 
of MED12 showed that mutant messenger ribonucleic acid (mRNA) escapes nonsense 
mediated decay (NMD) and produces an N-terminally truncated protein product. 
Immunofluorescence staining revealed that the mutation prevents the protein’s nuclear 
localization, and, in line with this observation, affinity purification mass spectrometry 
(AP-MS) analysis showed lost interactions between the mutant protein and other 
Mediator complex components. A nuclear localization signal (NLS) occurring at the 
highly conserved N-terminal region of MED12 was predicted and functionally 
validated. These results suggest an important role for MED12 in normal cell functions 
and demonstrate that NMD caused by nonsense mutations in early exons can be 
avoided also in the somatic context. 
 
The results of this study further strengthen the role of MED12 in pathogenesis of 
uterine leiomyomas. These findings demonstrate that MED12 mutations are not 
restricted to benign hormone-dependent solid tumors, but can be found also in 
malignant tumors and in hematological diseases. Our results also provide new 










REVIEW OF THE LITERATURE 
1. Tumorigenesis 
Development and functions of the human body, every organ and tissue, are conducted 
through the strictly controlled interplay of individual cells in the organism. Cells are 
regulated by the protein and ribonucleic acid (RNA) products encoded based on the 
information stored in the genome or by signals coming from their immediate 
surroundings and environment. Errors in the genetic code, either inherited or 
somatically acquired mutations, can alter some of the main characteristics of the cell. 
A subset of these changes can give the cell a growth advantage or ability to evade 
programmed cell death (apoptosis), leading to clonal expansion. When these kinds of 
alterations accumulate in a single cell, the formation of a tumor can be initiated 
(Hanahan and Weinberg, 2000). The vast majority of mutations occur in the non-
coding and non-regulatory region of the genome and thus are neither advantageous 
nor harmful for the cell (Khurana et al., 2016). Some of the errors can be repaired by 
the cells’ own repair mechanisms or cells with detrimental properties can be 
eliminated. Changes promoting tumorigenesis do, however, occur and accumulate up 
to a level that only in Finland over 30,000 cancer cases are diagnosed every year 
(Finnish Cancer Registry, statistics). 
 
The specific capabilities that the neoplastic cells themselves have to reach, or harness 
the adjacent cells to provide them with, have been postulated for a malignant tumor 
development. These ‘hallmarks of cancer’ include sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, 
inducing angiogenesis, and ultimately activating invasion and metastasis (Hanahan 
and Weinberg, 2000; Hanahan and Weinberg, 2011). In addition, reprogramming of 
cellular energetics and avoiding immunological destruction are recognized as 
emerging hallmarks relevant in many, if not all, cancers. Genomic instability and 
tumor-promoting inflammation are described as characteristics enabling the 
acquisition of these hallmarks (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 
2011). Benign tumors differ from malignant cancer only in their incapability to invade 
surrounding tissues and metastasize to different sites in the body. Although benign 
tumors remain within the originating tissue, they can reach a detrimental size or be 
located in a manner that may cause severe symptoms to the patient (Arafah and 
Nasrallah, 2001; Stewart, 2015). Generally benign tumors do not dedifferentiate from 
the originating tissue at similar scale as seen with malignant tumors, and thus they 
may exert the original function of the tissue, for instance hormone secretion, at 
abnormal and potentially harmful levels (Arafah and Nasrallah, 2001).  
 
In tumor tissue, cancer cells thrive in association with various different cell types, such 
as endothelial cells, infiltrating immune cells, and cancer-associated fibroblasts. Non-
malignant cells together with transformed tumor cells constitute the tumor 
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microenvironment that co-evolves and contributes to the progression and growth of 
the primary tumor and its ability to invade and resist treatment (Hanahan and 
Coussens, 2012; Junttila and de Sauvage, 2013). Varying composition of the cells, 
partly due to the environmental differences between distinct regions of the lesion, 
creates phenotypic and functional intratumoral heterogeneity. These are also affected 
by genetic heterogeneity, which refers to the different genomic composition of the 
tumor cells in distinct subclones within the same lesion. Genetic and epigenetic 
changes as well as heterotypic signaling between cancer cells and the 
microenvironment occur both in spatial and temporal contexts, leading to intratumoral 
heterogeneity and tumor evolution. The resulting plasticity allows tumors to adapt to 
differing environmental pressures, fostering, for instance, tumor growth, 
dissemination, and therapeutic resistance (Junttila and de Sauvage, 2013; McGranahan 
and Swanton, 2015). A proposed model of branched tumor evolution, in which 
subclones are separated by branching and diverge from each other through the 
acquisition of novel mutations, better explains intratumoral heterogeneity than the 
conventional linear model with sequential mutation accumulation to a single cell 
(Swanton, 2012). 
2. Genetics of cancer 
Mutations in the genome occur spontaneously in every cell cycle with a context-
dependent mutation rate that varies throughout the genome. Mutation rate correlates 
with characteristics such as chromatin organization, gene expression level, and the 
timing of replication in a way that regions with more heterochromatin-like 
architecture, low-level expression, and late replication timing have the highest rate 
(Stamatoyannopoulos et al., 2009; Schuster-Bockler and Lehner, 2012; Lawrence et 
al., 2013; Watson et al., 2013). Environmental carcinogens, including for example 
ultraviolet light and radon gas, as well as lifestyle-dependent factors such as smoking 
and alcohol consumption, cause mutations and increase the risk of the neoplastic 
transformation of a cell. A mutation providing a selective growth advantage is 
considered to be a driver mutation, promoting the transformation of the cell into a 
neoplastic form. Several driver mutations, each adding to the profitable features of the 
deriving cell clone, are required. Other mutations accumulating in the cell before the 
neoplastic shift, or along the process, are so-called passenger mutations without any 
essential contribution to tumorigenesis (Thiagalingam et al., 1996; Greenman et al., 
2007; Vogelstein et al., 2013). Based on recent large-scale sequencing studies on 
different cancers, approximately 200 ‘cancer genes’ with driver mutations have been 
identified, all involved in central cellular processes: maintenance of genome integrity, 
regulation of a cell’s fate (differentiation status), and survival (Vogelstein et al., 2013; 
Vogelstein and Kinzler, 2015). It has been estimated that on average two to eight 
driver gene mutations are present in a full-fledged malignant tumor, while the vast 
majority of the somatic variation is composed of passenger mutations (Vogelstein et 
al., 2013). The acquirement of the needed driver mutations and thus the development 




can last several years or even decades. At the end, the frequency of acquired mutations 
varies greatly between cancer types, with pediatric cancers and hematological 
malignancies having the lowest and cancers with strong environmental component, 
for example lung cancer and melanoma, harboring the highest number of mutations 
(Lawrence et al., 2013; Vogelstein et al., 2013; Watson et al., 2013). Mutation 
frequency also varies between patients with the same cancer type, for instance in the 
case of colorectal cancer where defects in deoxyribonucleic acid (DNA) mismatch 
repair or replication proofreading lead to a hypermutated state of some tumors (Cancer 
Genome Atlas Network, 2012; Lawrence et al., 2013; Palles et al., 2013). 
2.1 Genomic alterations 
A broad spectrum of mutations and aberrations can affect the genes or their regulatory 
regions relevant in tumor progression. The majority of the alterations observed in 
protein-coding genes of tumors are single nucleotide variations (SNV). Synonymous 
mutations do not change the amino acid encoded by the affected codon (nucleotide 
triplet), whereas missense or nonsense mutations result in a substitution of an amino 
acid or in a termination codon, respectively. Splice-site mutations affect the processing 
of the precursor messenger RNA (mRNA) leading to aberrant splicing, for example in 
the form of exon skipping or intron retention (Jung et al., 2015; Sveen et al., 2016). 
Synonymous mutations, although harmless in regard to the amino acid sequence, can 
also cause defects in splicing. These may also affect mRNA stability and translation 
speed as well as modify microRNA (miRNA) binding sites in coding and untranslated 
regions (Diederichs et al., 2016). Small scale insertions (ins) and deletions (del), less 
than 50 base pairs in length, are also frequent in tumors. Changes that result in a 
varying number of complete codons and thus alter the amino acid sequence are called 
in-frame mutations. Insertions and deletions which alter the reading frame (frameshift 
mutations) usually lead to a premature termination codon and nonsense mediated 
decay (NMD) or a truncated protein product. When occurring in regulatory regions 
(promoters, enhancers, silencers, insulators), these changes can affect the transcription 
by altering the transcription factor binding sites or interactions between regulatory 
elements (Diederichs et al., 2016; Khurana et al., 2016).   
 
Chromosome-level alterations include broader genomic rearrangements such as 
deletions, amplifications, translocations, insertions, and inversions. These aberrations 
can affect genes at the exon level or involve one or multiple genes or even larger 
chromosomal areas. Such rearrangements, as well as chromosomal aneuploidy 
(changes in the chromosome number), are frequently observed in cancer (Vogelstein 
and Kinzler, 2004; Negrini et al., 2010; Vogelstein et al., 2013). Chromotripsis is a 
highly complex manifestation of the chromosomal instability, where one or a few 
chromosomes are shattered into small fragments and subsequently reassembled 
randomly (Stephens et al., 2011). This phenomenon is established in tumor 
development and challenges the conventional conception of the sequential 
accumulation of genetic alterations (Kloosterman et al., 2014). A high rate of somatic 
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variation in tumors, generally referred to as genomic instability, can also be caused by 
microsatellite instability (MSI). Microsatellites are tandemly repeated short nucleotide 
sequences occurring throughout the genome. In MSI, an impaired DNA mismatch 
repair system is unable to correct the erroneous number of nucleotide repeats arising 
during DNA replication (Boland and Goel, 2010). A multitude of mutations can be 
also induced by defective proof-reading mechanisms of polymerases ε and δ (POLE 
and POLD1), leading to a hypermutated phenotype as mentioned above (Cancer 
Genome Atlas Network, 2012; Palles et al., 2013). Excessive accumulation of somatic 
substitution mutations, mainly cytosine (C) to thymine (T) transitions in the vicinity 
of chromosomal rearrangements, was observed initially in breast cancer and termed 
Kataegis (Nik-Zainal et al., 2012). The mutagenic effect of APOBEC DNA cytosine 
deaminases has been implicated in the phenomenon, although the exact underlying 
mechanism is yet unclear (Burns et al., 2013). 
2.2 Epigenetic and other changes in tumorigenesis 
Other factors affecting the functions and regulation of cancer genes, mainly via altered 
expression, are epigenetic modifications, non-coding RNAs, and infectious agents. 
Epigenetic changes do not alter the DNA nucleotide sequence but regulate gene 
expression through mechanisms acting on the genome such as DNA methylation, 
histone modification, and chromatin remodeling (Choi and Lee, 2013). Epigenetics 
has a fundamental role in development and it is becoming more evident also in 
tumorigenesis. Indeed, it has very recently been observed that some pediatric tumors 
and hematological malignancies may be driven mainly by epigenetic changes (Lee et 
al., 2012; Feinberg et al., 2016). Genes and regulatory sequences involved in 
epigenetics can be classified by their function as modulators, modifiers, and mediators 
(Feinberg et al., 2016). Epigenetic modifiers are responsible for the actual epigenetic 
modifications, for instance by attaching the methyl groups to cytosine bases, most 
commonly in the context of CpG dinucleotides, or introducing or removing methyl 
and acetyl groups involved in histone modification (Choi and Lee, 2013; Feinberg et 
al., 2016). Mediators are factors that are regulated by these modifiers and whose 
altered expression promotes tumorigenesis. Upstream of these two groups are the 
epigenetic modulators that regulate the activity of the epigenetic machinery in a 
response to stress signals and, in the context of cancer, push the cell towards a 
neoplastic form (Feinberg et al., 2016). Similarly as with somatic mutations, 
epigenetic changes can be identified as driver or passenger changes, with the majority 
being mere passengers (Pon and Marra, 2015). As an example of a driver change 
affecting an epigenetic mediator would serve promoter hypermethylation and 
subsequent inactivation of BRCA1 which has been recurrently observed in sporadic 
breast and ovarian carcinomas (Cancer Genome Atlas Research Network, 2011; 






Non-coding RNAs, particularly miRNAs and long non-coding RNAs (lncRNA), are 
implicated in tumorigenesis. MiRNAs are short transcripts which are able to bind to 
mRNAs of protein coding genes and repress their translation. In cancer, miRNA 
function can be affected through changes in their coding sequence, expression, or in 
their respective binding sites (Diederichs et al., 2016; Khurana et al., 2016). Over 200 
nucleotides long lncRNAs have several roles in cancer biology, for instance through 
epigenetic regulation, the p53 pathway, and the modulation of miRNA function 
(Evans et al 2016). Deregulated expression of lncRNAs has been observed in various 
cancers, but the exact mechanisms and impact in tumorigenesis largely remain to be 
unraveled (Diederichs et al., 2016; Khurana et al., 2016). A well-known example of 
the role of infectious agents in cancer development is the human papillomaviruses 
(HPV) in cervical cancer (Bosch et al., 2002). Expression of the HPV proteins E6 and 
E7 in epithelial cells leads to degradation of TP53 and the retinoblastoma proteins 
RB1, RBL1, and RBL2 and subsequently to continuous cell cycle progression and 
decreased apoptosis. The resulting genomic instability and enhanced cell proliferation 
drive the malignant transformation, where effective immune evasion is also essential 
(Crosbie et al 2013). HPV DNA can be detected in virtually all cervical cancers, and 
the majority are caused by two high-risk HPVs, HPV types 16 and 18 (Bosch et al., 
2002). 
2.3 Cancer genes 
Genes which most commonly drive tumor progression can be classified into 
oncogenes and tumor suppressor genes by their function and the change resulting from 
the mutation. Stability genes facilitating tumor development are also described as their 
own entity (Weinberg, 1994; Vogelstein and Kinzler, 2004; Croce, 2008). 
    2.3.1 Oncogenes 
Proto-oncogenes encode products that induce cell growth and proliferation or inhibit 
signals leading to cell-cycle arrest or elimination of a cell. In non-neoplastic cells, their 
expression is tightly controlled to maintain balanced cell growth within the tissue. As 
a result of an activating ‘gain-of-function’ mutation, a gene’s normal function is 
accelerated or abnormally activated, or neomorphic activity is acquired, after which 
the gene is depicted as an oncogene. Typical alterations affecting oncogenes are amino 
acid substitutions concentrating at specific residues, mutations in the regulatory 
region, amplifications, and chromosomal rearrangements causing overexpression or 
producing a novel fusion gene (Weinberg, 1994; Vogelstein and Kinzler, 2004; Croce, 
2008). For example, a point mutation affecting one of the critical codons in RAS genes 
(KRAS, HRAS, and NRAS coding for small GTPases) renders them constitutively 
active oncogenes leading to continuous cell growth (Pylayeva-Gupta et al., 2011). The 
Philadelphia chromosome is an example of an oncogene activation through formation 
of a fusion gene. A reciprocal translocation between chromosomes 22 and 9 creates 
the BCR-ABL1 fusion gene coding for a constantly active tyrosine kinase. 
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Rearrangement is observed in certain hematological malignancies, particularly in 
chronic myeloid leukemia (Advani and Pendergast, 2002). Activating mutations in 
proto-oncogenes are dominant as a single mutated allele is sufficient to provide the 
cell with a growth advantage (Weinberg, 1994; Vogelstein and Kinzler, 2004; Croce, 
2008).  
    2.3.2 Tumor suppressor genes 
Proteins or RNAs that negatively regulate proliferation or guide the cell to self-
destruction (‘gatekeepers’), or maintain the cellular microenvironment 
(‘landscapers’), are encoded by tumor suppressor genes (TSG) (Kinzler and 
Vogelstein, 1997; Kinzler and Vogelstein, 1998). Genetic alterations affecting these 
genes are usually inactivating ‘loss-of-function’ mutations that reduce or abolish the 
function of the gene. These include missense mutations affecting crucial amino acids, 
nonsense mutations, splice-site mutations, mutations in the regulatory region, subtle 
intragenic as well as large-scale deletions or insertions, and epigenetic silencing. In 
order to provide a cell with a selective growth advantage, generally both alleles of the 
tumor suppressor need to be inactivated (Vogelstein and Kinzler, 2004). This recessive 
model is characterized by Knudson’s two hit hypothesis, and is explicitly relevant in 
the majority of inherited cancer predisposition syndromes, where the other allele of 
the TSG is inactivated already in the germ line (Knudson, 1971). In the context of 
haploinsufficiency, inactivation of only one TSG allele is enough to promote 
tumorigenesis. In addition, some TSGs display dosage-dependency, where even a 
modest downregulation of the expression can be sufficient for tumorigenesis in a 
tissue-specific manner (Alimonti et al., 2010; Berger et al., 2011). For example, only 
a 20% reduction in PTEN expression has been shown to increase tumor susceptibility 
in mice, most notably the development of mammary tumors in females (Alimonti et 
al., 2010). A single mutated allele of a tumor suppressor can promote tumorigenesis 
also via a dominant-negative mode of action. This phenomenon is relevant with tumor 
suppressors that exert their effect by forming polymeric molecules, for instance with 
tumor protein p53 (TP53), where the product of the mutated allele is able to sequester 
also the wild-type product from its normal function (Willis et al., 2004; Payne and 
Kemp, 2005). 
 
Some genes may function as an oncogene or a tumor suppressor depending on the 
mutation and the tumor type. An example of this kind of bidirectional function is seen 
in the case of Notch (Drosophila) homolog 1 (translocation-associated) (NOTCH1), 
which, as a result of inactivating mutations, functions as a tumor suppressor in head 
and neck squamous cell carcinoma (Stransky et al., 2011), and as an activated 
oncogene in hematological malignancies, such as T-cell acute lymphoblastic leukemia 




    2.3.3 Stability genes 
Instead of regulating cell proliferation, a class of stability genes, also known as 
caretaker genes, sustain the genome integrity (Vogelstein and Kinzler, 2004). This 
class contains genes involved in the repair of nucleotide-level mistakes as well as 
genes controlling integrity at the chromosomal level, for example the segregation of 
the chromosomes. Inactivation of stability genes, typically through loss-of-function 
mutations in both alleles, leads to an increased mutation rate, thus potentiating the cell 
for tumorigenic changes. Mutations in stability genes are common in inherited tumor 
susceptibility syndromes. Accordingly, mutations in the mismatch repair genes 
MLH1, MSH2, MSH6, and PMS2 underlie hereditary non-polyposis colorectal cancer 
and endometrial cancer in Lynch syndrome (Sehgal et al., 2014), and mutations in the 
homologous recombination DNA repair genes BRCA1 and BRCA2 predispose to 
hereditary breast and ovarian cancers (HBOC) (Narod and Foulkes, 2004) 
2.4 Inherited susceptibility for cancer 
It is estimated that 5 to 10% of all cancer cases arise due to inherited susceptibility for 
cancer (Nagy et al., 2004). More than a hundred cancer predisposing genes (CPG) 
conferring high or moderate risk when mutated have been identified by to date 
(Rahman, 2014). Causative variants in these genes are estimated to account for 
approximately 3% of cancers. Individuals with germline mutations in CPGs may 
develop multiple primary tumors usually occurring at an earlier age. The inheritance 
pattern of cancer predisposition is autosomal dominant for the majority of CPGs, 
meaning that one affected allele is sufficient to cause the predisposition. Some genes, 
BRCA2 and MLH1, among others, predispose to pediatric tumors when both alleles 
harbor germline mutations, whereas monoallelic mutation carriers are prone to 
adulthood cancers after somatic inactivation of the wild-type allele (Wang et al., 1999; 
Howlett et al., 2002; Rahman and Scott, 2007). Most of the CPGs are affected by loss-
of-function mutations and act as tumor suppressors and specifically as stability genes 
(Rahman, 2014). Inactivating mutation in the germ line is usually a point mutation or 
a small-scale insertion or deletion. Inactivation of the wild-type allele in the tumor is 
most commonly conferred by loss of heterozygosity (LOH), which can be acquired 
through deletion of the region or copied and replaced from the homologous, mutation 
containing chromosome (copy-neutral LOH). Different mutations in one gene can 
confer different cancers. Activating promoter mutations in telomerase encoding TERT 
predisposes carriers to melanoma, whereas exonic mutations cause dyskeratosis 
congenita syndrome including predisposition for example to head and neck cancer and 
acute myeloid leukemia (AML) (Nelson and Bertuch, 2012; Horn et al., 2013). In 
addition, the cancer risk and the clinical phenotype can be modified by other genetic 
and non-genetic factors (Levy-Lahad and Friedman, 2007; Antoniou et al., 2008; 
Rahman, 2014; Jori et al., 2015). Approximately half of the CPGs containing high-to-
moderate risk variants are recognized to contribute to tumorigenesis also when 
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harboring only somatic mutations (Rahman, 2014). For instance, somatic alterations 
affecting the CPGs TP53 and RB1 are seen frequently in various cancer types. 
 
In addition to cancers associated with highly penetrant cancer syndromes, 15-20% of 
all common cancers are considered to be familial. Here, the clustering of certain 
cancers in a family is observed more often than would be expected by chance (Nagy 
et al., 2004). Variants conferring low or moderate risk for cancer predisposition, 
together with shared environmental factors, most likely underlie familial cancer 
accumulation. Genome-wide association studies including several thousands of cases 
and controls have identified an increasing number of common polymorphisms as low 
risk variants in most common cancers (Hosking et al., 2011). 
2.5 Genome-wide methods in cancer genetics 
Several technical revolutions have been seen in the field of molecular genetics during 
recent years. In cancer genetics, research has shifted from studying single or a limited 
number of genes in a given cancer, to describing mutational landscapes and expression 
profiles of different tumor types, and in clinical context further to deciphering the 
genomic composition of a certain tumor in a given patient. Microarrays are utilized in 
various high-throughput analyses to study for instance gene expression, copy number 
variation, DNA methylation, and histone modifications as well as in genotyping and 
miRNA profiling. Various applications are based on the detection of labeled target 
binding to a nucleotide probe attached on a solid surface. Traditional nucleotide 
sequencing methods have been accompanied by massive parallel sequencing 
applications, where a large amount of the genome is sequenced simultaneously. In 
whole exome sequencing (WES) virtually all of the protein-coding genome is captured 
for sequencing. Sequencing can alternatively be targeted to more restricted scope, 
covering for instance only a panel of cancer associated genes. In whole genome 
sequencing (WGS) both the coding (~1.5%) and the non-coding (~98.5%) part of the 
genome is sequenced. The DNA sequence is fragmented, ligated with synthetic 
adapters, amplified, and sequenced in parallel. These sensitive, high-throughput next-
generation sequencing (NGS) technologies have resulted in an unprecedented ability 
to study genomic variation in tumors. As methods are evolving and becoming more 
feasible and inexpensive, they are becoming more common not only in research 
settings but also in clinical diagnostics. By the year 2015, over 10,000 cancer exomes 
and more than 2,500 cancer genomes had been sequenced by individual research 
groups or collaborative sequencing programs such as The Cancer Genome Atlas 
(TCGA) and the International Cancer Genome Consortium (ICGC) (Martincorena and 
Campbell, 2015). These efforts are generating abundant data about somatic changes 
and mutational processes involved in the tumorigenesis of specific tumor types. 
Acquired information on cancer-related mutations and rearrangements in individual 
samples are repositoried in public databases, for instance in COSMIC (Forbes et al., 




3. Uterine leiomyomas 
Uterine leiomyomas, or uterine fibroids, represent one of the most common tumor 
types in women. The estimates of their overall prevalence vary form 20% to over 70% 
by the age of 50, and they are clinically relevant in one quarter of women (Cramer and 
Patel, 1990; Day Baird et al., 2003). Uterine leiomyomas originate from the smooth 
muscle cells of the myometrium and present as benign tumors with a considerable 
portion of extracellular matrix (ECM). Lesions can occur in different sections of the 
uterine wall as submucous (intracavitary), subserous, or intramural leiomyomas 
(Figure 1), and they may also represent a mixed type in regards to their location 
(Bajekal and Li, 2000; Stewart et al., 2016). Tumors vary greatly in size (up to 20 cm 
in diameter), and they can be present as individual or typically as multiple lesions 
within the uterus (Cramer and Patel, 1990; Day Baird et al., 2003; Heinonen et al., 
2014). The spectrum of symptoms caused by these common tumors include for 
instance abnormal uterine bleeding, discomfort and pain in the pelvic and abdominal 
areas, and urinary incontinence (Stewart et al., 2016). Uterine leiomyomas may also 
interfere with the implantation of the embryo and cause complications during 
pregnancy or labor, especially in the context of submucous leiomyomas (Bajekal and 
Li, 2000; Pritts et al., 2009). The severity of the symptoms depends on the number, 
location, and size of the leiomyomas. Because of the notable morbidity to women and 
the lack of highly specific and long-lasting medical treatments, hysterectomy remains 
the most common option to deal with the symptoms caused by uterine leiomyomas. 
Myomectomy or uterine artery embolization are preferred among younger women 
who wish to maintain their reproductive capability. Medication is applied mainly as a 
short-term treatment to scale down the symptoms as well as to reduce the tumor size 
before the surgical operation (Stewart, 2015). Solely direct medical costs caused 
annually by uterine leiomyomas have been estimated to be $4.1-9.4 billion in the US 







Figure 1. The main types of 
uterine leiomyomas based on their 
distinct locations in the uterus. 
Figure was retrieved August 8th from 
the NHS Choices web site 
(http://www.nhs.uk/ Conditions/ 
Fibroids /Pages /Introduction. aspx) 
and is reproduced with the 
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3.1 Development of uterine leiomyomas 
The development and growth of uterine leiomyomas are strongly dependent on the 
female hormones estrogen and progesterone (recently reviewed in Moravek et al., 
2015). In accordance, lesions are most prevalent during the reproductive age and 
usually shrink along with menopause (Parazzini et al., 1988; Cramer and Patel, 1990; 
Flake et al., 2003). Nulliparity and early onset of regular menstrual cycles are risk 
factors for uterine leiomyomas, while multiparity and later menarche have been 
associated with reduced risk (Parazzini et al., 1988; Parazzini et al., 1996; Marshall et 
al., 1998; Sato et al., 2000; Faerstein et al., 2001; Terry et al., 2010). Also, a high 
body mass index and hypertension have been suggested as risk factors for developing 
leiomyomas (Summers et al., 1971; Ross et al., 1986; Shikora et al., 1991; Faerstein 
et al., 2001; Wise et al., 2005). Inherited genetic factors contribute to the risk as well, 
since women whose first-degree relatives are diagnosed with uterine leiomyomas have 
elevated risk of developing leiomyomas (Vikhlyaeva et al., 1995; Sato et al., 2002). 
In addition, ethnicity strongly influences the probability of leiomyomas. Among 
African-American women, uterine leiomyomas are more common (cumulative 
incidence by age 50 >80% compared to ~70% in Caucasian women), develop earlier, 
and furthermore appear to be more symptomatic than in Caucasian women (Kjerulff 
et al., 1996; Faerstein et al., 2001; Day Baird et al., 2003). 
 
Traditionally, uterine leiomyomas have been considered as monoclonal tumors 
originating from one single cell (Linder and Gartler, 1965; Townsend et al., 1970; 
Zhang et al., 2006). In some cases, multiple tumors within a single uterus have been 
observed with shared clonal origin, demonstrating a possibility of leiomyoma 
dissemination (Nilbert et al., 1990; Canevari et al., 2005; Mehine et al., 2013; Mehine 
et al., 2015). The exact origins and mechanisms of initiation are still unresolved issues 
in the development of leiomyomas. Recent studies identifying stem cell-resembling 
cell populations in the context of both the myometrium and leiomyoma have 
postulated a hypothesis whereby each lesion originates from a single transformed 
myometrial stem cell and possibly gains further growth advantage through additional 
genetic changes occurring in the developing tumor (Ono et al., 2007; Ono et al., 
2014a). 
 
In addition to conventional uterine leiomyomas, which account for ~90% of all 
tumors, several histopathological subtypes with distinct morphological features or 
unusual growth patterns are recognized (Oliva et al., 2014). Some variants, for 
instance mitotically active, with bizarre nuclei (formerly called atypical), cellular and 
highly cellular uterine leiomyomas present histopathologically different 
characteristics that resemble malignancy, yet as a whole, these tumors are considered 
benign (Oliva et al., 2014). True, and moreover highly malignant, counterpart of 
uterine leiomyoma is leiomyosarcoma of the myometrium. These tumors usually 
display morphological features that are seen in distinct uterine leiomyoma subtypes 
(increased mitotic activity, nuclear atypia, and high cellularity) as well as tumor cell 




of less than 0.4 cases/100,000 women, but unfortunately it is usually diagnosed in 
pathological examination only after the appearance of surgery-requiring severe 
symptoms (Toro et al., 2006; Koivisto-Korander et al., 2012). 
3.2 Chromosomal alterations in uterine leiomyomas 
Nearly half of uterine leiomyomas present different chromosomal aberrations (Nibert 
and Heim, 1990; Vanni et al., 1991; Rein et al., 1991; Sandberg, 2005a). Recurrent 
non-random rearrangements affect for example the high-mobility group AT-hook 1 
and 2 genes at 6q21 (HMGA1) and at 12q15 (HMGA2), accounting for ~5% and ~20% 
of cytogenetically aberrant lesions, respectively (Meloni et al., 1992; Van de Ven, 
1998; Ligon and Morton, 2000). The HMGA2 locus-containing region at 12q13-15 is 
recurrently altered also in other benign tumors of mesenchymal origin, such as 
lipomas, endometrial polyps, and breast fibroadenomas (Vanni et al., 1993; 
Schoenmakers et al., 1994; Schoenmakers et al., 1995; Dal Cin et al., 1995; Staats et 
al., 1996; Sandberg, 2005a). In uterine leiomyomas, the most commonly observed 
rearrangement is the reciprocal translocation between chromosomes 12 and 14, 
t(12;14)(q14-q15;q23-q24), where RAD51 homolog B (RAD51B) at 14q23-24 
constitutes the translocation partner for HMGA2 (Vanni et al., 1991; Rein et al., 1991; 
Ingraham et al., 1999; Schoenmakers et al., 1999; Quade et al., 2003). This, as well 
as other rearrangements affecting the HMGA2 locus or the region upstream to it, 
usually lead to overexpression of the gene (Gattas et al., 1999; Tallini et al., 2000; 
Quade et al., 2003). HMGA2 is also overexpressed in uterine leiomyomas without 
aberrations affecting 12q14-15, possibly through altered functions of the HMGA2-
repressive miRNA let-7 (Mayr et al., 2007; Peng et al., 2008; Klemke et al., 2009). 
Overexpression of HMGA proteins is associated with a highly malignant phenotype 
in several malignant tumor types (Pallante et al., 2015). HMGA proteins modify the 
chromatin conformation and thus function as indirect regulators of transcription 
(Fusco and Fedele, 2007), whereas RAD51B is a DNA repair protein involved in 
homologous recombination of double-strand DNA breaks (Albala et al., 1997; Suwaki 
et al., 2011). 
 
Other recurrently observed cytogenetic aberrations in uterine leiomyomas are the 
trisomy of chromosome 12 and rearrangements affecting the long arm (q) of 
chromosome 7 (Boghosian et al., 1988; Vanni et al., 1989; Vanni et al., 1992; 
Sandberg, 2005a). The minimal region commonly deleted at 7q has been mapped to 
7q22, wherein cutlike homeobox 1 (CUX1) has been identified as the most likely target 
gene affected by various rearrangements (Zeng et al., 1997; Schoenmakers et al., 
2013; Mehine et al., 2013). The CUX1 transcription factor regulates cell proliferation 
and invasion, among other cellular processes (Hulea and Nepveu, 2012), and in 
addition to its putative role in uterine leiomyomas it has been implicated as a 
haploinsufficient tumor suppressor in myeloid cancers (McNerney et al., 2013; Wong 
et al., 2014). In a small number of uterine leiomyomas alterations affecting collagen 
component-coding genes collagen type IV alpha 5 and alpha 6 (COL4A5 and 
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COL4A6) on the X chromosome have been identified (Mehine et al., 2013). Germline 
alterations in these genes lead to a rare condition known as Alport syndrome and 
diffuse leiomyomatosis, predisposing patients to leiomyomas of various organs 
(Garcia-Torres et al., 2000; Thielen et al., 2003). Some of the above-mentioned 
chromosomal rearrangements, as well as less frequent alterations in uterine 
leiomyomas affecting chromosomes 1, 3, 10, 13, and X, may co-occur with the more 
prevalent cytogenetic changes (Sandberg, 2005a; Mehine et al., 2013). Alterations 
occurring in addition to the primary tumorigenic events are considered to be secondary 
changes which are not required but are advantageous for the tumor.  
3.3 Hereditary leiomyomatosis and renal cell cancer syndrome 
Biallelic inactivation of fumarate hydratase (FH) is additional, although very rare, 
event underlying the development of uterine leiomyomas. This phenomenon usually 
occurs in the context of a tumor predisposition syndrome, hereditary leiomyomatosis 
and renal cell cancer (HLRCC, Mendelian Inheritance in Man [MIM] database 
150800). HLRCC is an autosomal dominant syndrome where heterozygous germline 
mutations in the FH gene predispose mutation carriers to cutaneous and uterine 
leiomyomas and in some families also to aggressive renal cell cancer (Kiuru et al., 
2001; Launonen et al., 2001; Alam et al., 2001; Tomlinson et al., 2002). FH locates 
to 1q43 and encodes the fumarate hydratase enzyme. In its homotetramer form, it 
functions as a catalyst in tricarboxylic acid cycle (TCAC) hydrating fumarate to 
malate. Germline mutations are mainly missense and nonsense point mutations 
occurring throughout the gene. Frameshift mutations, splice-site mutations, and 
deletions removing the entire gene or part of it have also been observed (Alam et al., 
2005b; Wei et al., 2006; Bayley et al., 2008; Ahvenainen et al., 2008; Gardie et al., 
2011; Smit et al., 2011). FH is a tumor suppressor, and, accordingly, biallelic 
inactivation of the gene is observed in syndrome-associated tumors. The wild-type 
allele is most commonly lost through LOH (Kiuru et al., 2001; Launonen et al., 2001; 
Tomlinson et al., 2002; Alam et al., 2003). Somatic point mutations are also observed 
as a second hit, and occasionally both alleles are inactivated through somatic events 
(Kiuru et al., 2002; Lehtonen et al., 2004; Harrison et al., 2015). Homozygous or 
compound heterozygous germline mutations in FH cause fumarase deficiency 
syndrome (FHD, MIM 606812) with severe neurological impairment that usually 
leads to death in early childhood (Zinn et al., 1986; Bourgeron et al., 1994). 
 
Cutaneous leiomyomas (piloleiomyomas) are the most prevalent feature of HLRCC 
syndrome. Uterine leiomyomas are present in the great majority of women with 
HLRCC (Toro et al., 2003; Alam et al., 2005a; Wei et al., 2006; Stewart et al., 2008). 
Syndrome-associated FH-deficient uterine leiomyomas are characterized by particular 
clinical and morphological features compared to sporadic leiomyomas. Tumors are 
usually more numerous and they are diagnosed earlier in HLRCC patients. In general, 
they are more symptomatic than their sporadic counterparts and thus require surgical 




et al., 2006; Stewart et al., 2008; Lehtonen, 2011). HLRCC-associated uterine 
leiomyomas represent characteristics of histopathological subtypes, typically those of 
leiomyomas with bizarre nuclei or cellular leiomyomas, whereas atypical mitoses and 
tumor cell necrosis, defining malignancy, are not observed. In addition, cell density 
and organization of the ECM is observed to be higher in these tumors. Similar nuclear 
features as described in syndrome-associated renal cell cancers are also present in 
uterine leiomyoma cells, including prominent eosinophilic nucleoli and clear haloes 
surrounding them, and an ovoid shape of the nuclei (Launonen et al., 2001; Sanz-
Ortega et al., 2013; Joseph et al., 2015). Characteristics vary, however, to the extent 
that identification of syndrome-associated leiomyomas is not feasible solely based on 
morphological criteria (Alsolami et al., 2014). Renal cell cancer is observed only in a 
subset of HLRCC families, and more frequent occurrence has been noted in families 
from Finland and the US. HLRCC-associated renal cell cancers develop at a younger 
age, are highly aggressive, and represent usually type 2 papillary histology (Launonen 
et al., 2001; Tomlinson et al., 2002; Toro et al., 2003; Grubb et al., 2007; Vahteristo 
et al., 2010).  
 
The mechanisms underlying the pathogenesis of FH deficiency are not yet fully 
understood. One possible explanation may involve the stabilization of hypoxia-
inducible factor 1 alpha (HIF1A) by the accumulation of fumarate and subsequent 
activation of growth promoting hypoxia pathways (Isaacs et al., 2005; Pollard et al., 
2005; Pollard et al., 2007; Koivunen et al., 2007). Despite consistent stabilization of 
HIF1A in FH-deficient tissues, it has been observed that in the Fh1-deficient mice, 
formation of renal cysts is not dependent on Hif activities (Adam et al., 2011). An 
alternative tumorigenic route has been suggested, in which the accumulation of 
fumarate leads to succination of critical cysteine residues in KEAP1, stabilization of 
NRF2, and subsequent activation of the antioxidant response pathway (Adam et al., 
2011; Ooi et al., 2011; Taguchi et al., 2011). Succination, a stable modification of 
cysteine residues to S-(2-succinyl)-cysteine (2SC), is a direct and specific 
consequence of elevated fumarate levels in the cell and can be robustly detected with 
an antibody raised against it (Nagai et al., 2007; Frizzell et al., 2011; Bardella et al., 
2011). 
3.4 MED12 mutations in uterine leiomyomas 
At the beginning of the next-generation sequencing era, WES was applied to 18 uterine 
leiomyomas and corresponding normal myometrium tissue samples from 17 Finnish 
patients. Analysis identified ten tumors with a somatic mutation in the mediator 
complex subunit 12 (MED12) gene (Mäkinen et al., 2011b). A validation set of 207 
uterine leiomyomas from 63 individual patients showed similar occurrence of somatic 
MED12 mutations, yielding a mutation frequency as high as 71% (159/225). All 
mutations were located at a very specific region in the gene comprising the end of the 
first intron and the beginning of the second exon. Nearly 70% of observed mutations 
were single nucleotide substitutions affecting codon 44, coding for a glycine amino 
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acid (G). Most of these mutations resulted in a replacement of this glycine residue 
with an aspartic acid residue (D), while all other possible amino acid substitutions 
were observed as well. The rest of the mutations were other missense mutations or 
small frame-retaining insertions and deletions. Codons 36 (leucine, L) and 43 
(glutamine, Q) as well as an intronic T nucleotide eight base pairs before the intron-
exon boundary formed additional mutation hotspots, albeit with substantially lower 
mutation frequencies. Mutations in any other part of the gene were not observed by 
WES nor by direct Sanger sequencing of 20 MED12 mutation-negative and 10 MED12 
mutation-positive samples. All observed mutations were heterozygous and 
complementary deoxyribonucleic acid (cDNA) sequencing of 16 MED12 mutation-
harboring tumors showed that the mutant allele of the X-chromosomal MED12 was 
predominantly expressed in all the tumors. In addition, cDNA sequencing verified the 
splice site effect of the intronic variant at nucleotide position c.100-8 as the six last 
intronic nucleotides were added to the transcript (Mäkinen et al., 2011b).  
 
Frequent MED12 mutations in uterine leiomyomas were studied also in a population 
with different ethnic backgrounds. Sanger sequencing-based analysis included 28 
uterine leiomyomas from 18 South African women: six black African women and 12 
women with mixed ancestry (colored) (Mäkinen et al., 2011a). Similar kinds of 
mutations affecting the same region of MED12 were observed in 50% of the tumors. 
The total mutation frequency was lower than that observed in uterine leiomyomas 
derived from Caucasian patients, but the difference leveled out when comparing 
tumors with a diameter ≥5.5 cm, which are predominant in women with African 
ancestry. Instead, a statistical difference in the mutation frequencies was observed 
when only smaller tumors (<5.5 cm) were analyzed (Mäkinen et al., 2011a). These 
compelling findings were soon validated also by the WES analysis of uterine 
leiomyomas from North American women. In this study, MED12 mutations were 
observed with a frequency of 68%. This study comprised both black and white 
American women, and here the MED12 mutation frequency was slightly higher 
among uterine leiomyomas from black American women, however not reaching 
statistical significance (McGuire et al., 2012). Again, all the observed mutations were 
missense mutations affecting the mutational hotspots identified in the Finnish study, 
or alternatively insertion/deletion mutations that did not change the reading frame. 
4. MED12 
MED12 is a large gene consisting of 45 coding exons spanning a genomic area of 24 
kb. It is located on the long arm of the X chromosome, at Xq13 
(X: 71,118,556 - 71,142,454) (Philibert et al., 1998; Philibert et al., 1999; Ensembl 
database: Homo sapiens, genome assembly GRCh38.p7, MED12). As an X-
chromosomal gene, MED12 is subjected to lyonization, a random inactivation of one 
of the two X-chromosomes in females. This process balances the expression of X-
linked genes between males and females, and it is irreversible in the particular cell and 




subunits, MED12 is conserved among eukaryotes, and in humans it is more conserved 
than average genes (Borggrefe et al., 2002; Kitano et al., 2003; Bourbon et al., 2004; 
Bourbon, 2008). The gene encodes a transcript of 6,795 base pairs, which is translated 
into the MED12 protein consisting of 2177 amino acids, with a molecular mass of 
243,081 Da (UniProt database: Q93074, MED12_Human; UniProt Consortium, 
2015). The amino acid sequence of MED12 is largely unique, and it is traditionally 
divided into four domains characterized by an enrichment of certain amino acids: a 
leucine-rich L domain (aa 1-500), a leucine-serine-rich LS domain (aa 501-1650), a 
proline-glutamine-leucine-rich PQL domain (aa 1651-2086), and a glutamine-rich 
opposite paired (OPA) domain (aa 2087-2177) (Zhou et al., 2002) (Figure 2A). The 
Med12-PQL domain is listed in the protein families (Pfam) database and is described 
as Eukaryotic Mediator 12 catenin binding site at amino acids 1819-2022 in MED12 
(Pfam database, MED12_Human; Finn et al., 2016). In the database, the Med12 and 
Med12-LCEWAV domains are also characterized in the human MED12 protein, at 
amino acids 104-161 and 286-757, respectively (Figure 2). Any specific functions of 
these domains have not been described, but they contain sequence motifs that are 
conserved in eukaryotes. MED12 is expressed at comparatively similar levels 
throughout a range of human tissues and in all developmental stages (Philibert et al., 
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Figure 2. Schematic representation of the human MED12 protein. A) The amino acid sequence is divided 
into four domains according to their prevailing amino acid content (L=leucine-rich; LS=leucine-serine-rich; 
PQL=proline-glutamine-leucine-rich; OPA=opposite paired domain). Domains listed in the Pfam database 
for MED12 are marked under the amino acid domain alignment. Binding sites for various interactors are 
recognized in the PQL domain. The first germline mutations identified in MED12-related XLID syndromes 
(FG, Lujan-Fryns, OSMKB) are marked above the alignment. Frequent somatic exon 2 mutations observed 
in uterine leiomyomas are indicated with a red arrow. B) The predicted 3D structure of MED12. Conserved 
domains identified in the protein are indicated as yellow (Med12), red (Med12-LCEWAV), and blue 
(Med12-PQL) ribbons. The 3D-structure is from the article of Banaganapalli et al., 2016, and is reproduced 
with the permission of the copyright holder 
4.1 MED12 as a subunit of the Mediator complex 
MED12 is a subunit of the Mediator, a large multiprotein complex exceeding a 
molecular weight of 1.8 MDa when containing all associated modules (Taatjes 2010). 
Mediator is a central regulator of RNA polymerase II (Pol II)-dependent transcription 
by forming a physical connection between regulatory elements and the transcription 
machinery. In addition to transmitting regulatory signals from DNA-bound 
transcription factors to Pol II, Mediator is involved in various steps along the 
transcription process, such as the organization of chromatin structure and in 
transcription initiation and elongation (Malik and Roeder, 2010; Allen and Taatjes, 
2015). The complex was initially discovered in the yeast Saccharomyces cerevisiae 
and has since been observed to exist with a highly conserved composition throughout 
eukaryotes (Myers and Kornberg, 2000; Bourbon, 2008; Tsai et al., 2013; Tsai et al., 
2014; Allen and Taatjes, 2015). In higher eukaryotes, Mediator is composed of 30 
subunits, which are divided into four distinct modules according to their location and 
interactions within the complex. The core of the complex is formed by the ‘head’, 




enzyme (Asturias et al., 1999; Näär et al., 2002; Tsai et al., 2014). The fourth module, 
associating reversibly with the Mediator core, is the ‘CDK8 kinase module’ 
comprising Mediator subunit MED12, Mediator complex subunit 13 (MED13), Cyclin 
C (CCNC), and Cyclin-dependent kinase 8 or 19 (CDK8/19) (Borggrefe et al., 2002; 
Bourbon, 2008) (Figure 3).  
 
The CDK8 kinase activity of the module has been shown to disrupt the formation of 
the transcription preinitiation complex by phosphorylating the Pol II carboxy-terminal 
domain (CTD) as well as to hinder the subsequent transcript initiation by 
phosphorylating the general transcription initiation factor IIH (Hengartner et al., 1998; 
Akoulitchev et al., 2000). In addition, when interacting with the core Mediator, the 
kinase module precludes Pol II binding, and thus, mostly suppressive regulation of 
transcription has been associated with it (Elmlund et al., 2006; Knuesel et al., 2009a). 
More recently, the kinase module has been implicated as an activator of transcription 
in several instances, such as in the p53 network (Donner et al., 2007), in the HIFA 
mediated hypoxia response (Galbraith et al., 2013), and in wingless-related integration 
site (Wnt)/β-catenin signaling (Kim et al., 2006; Galbraith et al., 2010; Clark et al., 
2015). The detailed mechanisms of kinase module-mediated transcription activation 
are not yet fully understood, but they might involve precise scheduling of Pol 
II/Mediator interactions and kinase module recruitment or alternatively rely on 
structural changes in the Mediator itself (Galbraith et al., 2013; Tsai et al., 2014; Wang 
et al., 2014b). Electron microscopic imaging and immunochemical analyses showed 
MED13 to be the main link between the kinase module and the Mediator core, 
especially the middle module of the Mediator. In the kinase module, MED12 is in the 
center of the module, connecting the Cyclin C/CDK8 pair to MED13 (Tsai et al., 
2013). MED12 has been shown to be required for the kinase activity of CDK8 in 
higher eukaryotes. While the majority of the kinase modules function in association 
with the Mediator, a proportion exist as discrete modules, retaining their kinase 
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Figure 3. Schematic representation of the Mediator core and CDK8 kinase module. The human 
Mediator complex comprises 30 subunits. MED12 is a subunit of the CDK8 kinase module, which it forms 
together with MED13, Cyclin C, and CDK8/19. Division of the Mediator core subunits into head, middle, 
and tail modules is adapted from the study of Tsai et al., 2014. 
Paralogs for the kinase module subunits CDK8, MED12, and MED13 have been 
identified in vertebrates (Sato et al., 2004; Bourbon, 2008; Tsutsui et al., 2008; Clark 
et al., 2015). MED12 paralog MED12L on chromosome 3 was initially identified as 
NOPAR (no OPA repeat), with 61% sequence homology but without the OPA domain 
found in original MED12 (Joensuu et al., 2001). The PQL and OPA domains were 
recently identified also in the paralog, thereafter named MED12L (Vogl et al., 2013). 
The same conserved domains (Med12, Med12-LCEWAV, and Med12-PQL) are listed 
in the Pfam database for both MED12 and MED12L. Of the kinase module subunits, 
CDK8 paralog CDK19 most closely resembles its counterpart. Their amino acid 
similarity exceeds 90% at the kinase domain and shows high conservation among 
vertebrates (Manning et al., 2002; Tsutsui et al., 2008). Overlapping expression-
regulating functions have been described to these proteins (e.g. Pol II CTD 
phosphorylation), while unique targets in context-dependent settings also exist 
(Tsutsui et al., 2011). Moreover, opposing functions for these subunits have been 
observed in viral transcription activator VP16-dependent transcription (Tsutsui et al., 
2008).  
4.2 MED12 in signaling pathways 
Only a few functional domains have been described in MED12 (Figure 2). The protein 
region containing amino acids 1651-2086, covering the Med12-PQL domain, have 
been identified as a direct binding target for the β-catenin transactivation domain (Kim 
et al., 2006). Through this interaction, MED12 and the Mediator complex are recruited 
to activate target gene transcription in canonical Wnt/β-catenin signaling. The 
relevance of Med12 to Wnt/β-catenin signaling as well as Wnt/planar cell polarity 




embryos showed severe defects in the developmental events regulated by these 
signaling pathways (Rocha et al., 2010).  
 
In addition to the well-established interaction with β-catenin, MED12 has been 
implicated in a few other signaling pathways, with an emphasis on developmental 
signaling (Yin and Wang, 2014; Clark et al., 2015). The carboxy (C) -terminal area of 
MED12 containing the PQL domain has been identified as a binding region also for 
the Sox9 and Sox10 transcription factors, thus linking MED12 for example to the 
developmental regulation of the nervous system and chondrocyte differentiation in 
which designated Sox family members are involved (Zhou et al., 2002; Rau et al., 
2006; Wang et al., 2006; Vogl et al., 2013). Other members of Sox family, Sox32 and 
Sox4b, have also been implicated to be regulated by Med12 in the development of the 
endoderm in Zebrafish (Shin et al., 2008). Furthermore, the MED12 PQL domain has 
been shown to physically interact with the Sonic hedgehog (Shh) signaling effector 
glioma-associated oncogene family zinc finger 3 (Gli3), more specifically with its 
MED12/Mediator binding transactivation domain (Zhou et al., 2006). Interaction 
between MED12 and activated Gli3 has been demonstrated to lead to Mediator-
dependent suppression of Shh target gene transcription (Zhou et al., 2006; Zhou et al., 
2012).  
 
MED12 has also been shown to exert repressive actions on transcription through 
epigenetic regulation. EHMT2 methyltransferase, also known as G9a, binds directly 
to the MED12 PQL domain and is connected through the Mediator core (more 
accurately through MED19 and MED26) to the RE1 silencing transcription factor 
(REST). This complex leads to transcriptional suppression of specific neuronal genes 
in non-neuronal cells via H3K9 histone di-methylation (Ding et al., 2008; Ding et al., 
2009). 
4.3 MED12 mutations in the germ line 
The gene coding for MED12 was initially described as a human OPA-containing gene 
(HOPA) because of the rare polymorphism in its OPA domain. This variant is an 
insertion of 12 base pairs in exon 43, leading to the addition of an extra QQHQ amino 
acid stretch to the glutamine-rich sequence of the region. Originally, the insertion was 
reported to be associated with an X-linked mental retardation and hypothyroidism 
syndrome (Philibert et al., 1998; Philibert et al., 1999), but instead an association with 
increased risk for schizophrenia was subsequently demonstrated (Philibert, 2006; 
Philibert et al., 2007).  
 
Germline mutations in MED12 have been connected to different X-linked intellectual 
disability (XLID) syndromes (Figure 2A). Missense mutations leading to substitutions 
R961W or G958E in the LS domain of MED12 underlie Opitz-Kaveggia syndrome, 
also named FG syndrome-1 (MIM 305450) (Opitz and Kaveggia, 1974; Risheg et al., 
2007; Rump et al., 2011). A nearby missense mutation affecting the same domain and 
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leading to an N1007S substitution has been identified in Lujan-Fryns syndrome (MIM 
309520) (Lujan et al., 1984; Fryns and Buttiens, 1987; Schwartz et al., 2007). These 
syndromes present a broad variety of clinical manifestations caused by developmental 
defects, with several overlapping symptoms, such as intellectual disability, 
malformation of the corpus callosum, macrocephaly, and a tall forehead (Graham and 
Schwartz, 2013). MED12 missense mutations causing both Opitz-Kaveggia and 
Lujan-Fryns syndromes have been shown to disrupt its function in REST-mediated 
gene silencing as well as in Gli3-dependent Shh signaling (Ding et al., 2008; Zhou et 
al., 2012). 
 
At least three different MED12 missense mutations causing amino acid changes at the 
C-terminal end of MED12 (R1148H, S1165P, and H1729N) have been linked to 
Maat–Kievit–Brunner type Ohdo syndrome (OSMKB; MIM 300895). This syndrome 
is an X-linked subtype of blepharophimosis-intellectual disability syndromes with 
characteristic facial features as well as intellectual and developmental delays (Maat-
Kievit et al., 1993; Vulto-van Silfhout et al., 2013). Additional MED12 missense 
mutations, and recently also one frameshift mutation, have been linked to X-linked 
intellectual deficiency with milder syndromic features or with a different composition 
of manifestations than in previously described syndromes. In some families, 
intellectual impairment has also been observed in heterozygous females (Lesca et al., 
2013; Bouazzi et al., 2015; Langley et al., 2015; Prontera et al., 2016). Phenotypic 
variability and differing severity of the features between patients, even when linked to 
same MED12 mutation, implicate a spectrum of MED12-related disorders rather than 
separate syndromes (Isidor et al., 2014; Langley et al., 2015).  
4.4 Somatic MED12 mutations in other tumor types? 
Uterine leiomyomas are the first tumors where recurrent somatic MED12 mutations 
have been observed. The high mutation frequency and specific location of non-
truncating mutations further confirmed their essential role in the tumorigenesis of 
uterine leiomyomas. The smooth muscle cells of the myometrium that serve as 
progenitors for uterine leiomyomas originate from the mesenchymal tissue. The 
mesenchyme is formed mainly by the mesodermal germ layer and gives rise to the 
tissues of the circulatory and lymphatic systems as well as smooth muscles, bones, 
and cartilage. Another distinctive feature of uterine leiomyomas is their dependence 
on the steroid hormones estrogen and progesterone. A large proportion of other female 
tumors, especially those of the breasts, ovaries, and endometrium, are initially 
dependent on steroid hormones, although later in the development they might gain 
hormone-independency. Other tumor types deriving from tissues with mesenchymal 
origin, such as bone and cartilage sarcomas, leiomyosarcomas, leiomyomas of other 
organs, endometrial polyps, and lipomas, as well as estrogen and progesterone-
dependent tumors, might share similar mechanisms in tumorigenesis and harbor 





Preliminary gene expression and pathway enrichment analyses performed on MED12 
mutation-positive uterine leiomyomas suggested an involvement of aberrant Wnt 
signaling in leiomyomagenesis (Mäkinen et al., 2011b). Furthermore, as mentioned 
above, MED12 has been shown to bind directly with β-catenin and regulate the 
canonical Wnt/β-catenin signaling pathway (Kim et al., 2006). Dysregulation of Wnt 
signaling is one of the central mechanisms involved in human cancers. For example, 
the loss of APC function, both in the context of familial adenomatous polyposis and 
sporadic colorectal cancers, leads to the accumulation of β-catenin and activation of 
the Wnt signaling pathway (Polakis, 2012; Novellasdemunt et al., 2015). A role for 
MED12 has also been suggested in hematopoiesis as it has been observed to regulate 
the differentiation of certain myeloid lineage cells in Drosophila and zebrafish (Gobert 
et al., 2010; Keightley et al., 2011). In addition, retroviral insertions affecting the 
Med12 locus have been identified in mice with leukemia (Dave et al., 2009). After the 
initial identification of somatic MED12 mutations, relevant expression data stored in 
public repositories was analyzed utilizing the Genesapiens database (now 
Medisapiens). The database contained gene expression data from 175 human tissues 
(43 normal tissue types, 68 cancer types, and 64 other diseases) collected from nearly 
10,000 expression array experiments (Kilpinen et al., 2008). Analysis revealed 
MED12 expression to be clearly upregulated in the leukemia subtypes AML and ALL 
in comparison with other tumor types. Based on these observations, tumors with 
aberrant Wnt signaling as well as hematological diseases compose yet additional 
groups of neoplasms where MED12 mutations might play a role.  
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AIMS OF THE STUDY 
The overall aim of this thesis project was to take forward the recent finding of MED12 
as a novel driver gene in myomagenesis and to analyze its role in other tumor types. 
The aim was also to investigate the functional impacts of the observed mutations and 
to shed light on the normal functions of MED12.  
 
The specific aims were as follows: 
 
1. To study the role of MED12 exon 2 mutations in various tumor types 
 
2. To investigate if mutations also exist in exon 1 of MED12 and if they share the 
same functional effect as exon 2 mutations 
 
3. To study the role of MED12 in the tumorigenesis of HLRCC patients’ uterine 
leiomyomas and to analyze if MED12 mutations and biallelic FH inactivation 
are mutually exclusive 
 
4. To analyze the mechanistic effects of the unusual MED12 exon 1 nonsense 




MATERIALS AND METHODS 
1. Study subjects and samples 
1.1 Tumor samples (I-V) 
In total, 2259 tumor samples, both benign and malignant, were included in the 
mutation screenings performed in studies I-IV. The sample series consisted of 
mesenchymal tumors, estrogen-progesterone dependent tumors, hematological 
malignancies, and colorectal cancer samples (Table 1). 
 
In Study I, 1158 tumor samples were screened for MED12 exon 2 mutations. The 
sample series included uterine leiomyosarcomas and other sarcomas, gastrointestinal 
stromal tumors, extrauterine leiomyomas, endometrial polyps, lipomas, ovarian 
cancers, breast cancers, acute myeloid leukemias, acute lymphoblastic leukemias, 
myeloproliferative neoplasms, and colorectal cancers. The series was collected from 
several university and central hospitals in Finland, Denmark, and the United States. 
The samples were obtained either as preserved tumor samples (fresh frozen, FF, or 
formalin-fixed paraffin-embedded, FFPE) or as ready-extracted DNA. Samples of 
AML and myeloproliferative neoplasms from Memorial Sloan-Kettering Cancer 
Center, NY, USA, were extracted and analyzed at the institution’s facilities. 
 
In Study II, 611 samples previously identified as MED12 exon 2 mutation-negative, 
were screened for mutations in exon 1 of the gene. The sample series consisted of 
uterine leiomyomas, extrauterine leiomyomas, endometrial polyps, uterine 
leiomyosarcomas, other sarcomas, and colorectal cancer samples, representing all the 
tumor types where recurrent MED12 exon 2 mutations had been observed until then. 
 
Altogether, 188 uterine leiomyoma samples were screened for MED12 exon 1/2 
mutations and their FH status was analyzed in Study III. Of these, 122 were from 27 
Finnish HLRCC patients representing 11 families (89 FFPE and 33 FF samples) and 
66 were sporadic uterine leiomyoma samples (FFPE) from as many individuals. 
HLRCC families included in the study are listed in Table 2. 
 
Three independent sample series comprising 746 CLL samples were collected for 
MED12 exon 1 and 2 mutation screening in Study IV. Two of the series were collected 
from the United States, from the Tissue Core Biorepository of CLL Research 
Consortium (CRC; 278 samples) and The Ohio State University’s Human Genetics 
Sample Bank (292 samples). US samples were extracted and sequenced at the 
respective institutions. The third sample series was collected from the Helsinki 
University Central Hospital clinical sample collection (176 samples). More detailed 
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information about the series and the collection procedures can be found in the 
Supplementary Data of the original publication IV.  
 
In Study V, one T-ALL patient sample harboring a MED12 nonsense mutation 
(c.97G>T, p.E33X) (Kontro et al., 2014) served as the study material in addition to 




Tumor type n (study) Sample type Samples from Reference 
Tumors of mesenchymal origin 
Uterine Leiomyosarcoma 
  Early  onset 
  Unselected 
40 
   27 (I), 24 (II) 
   12 (I), 13 (II) 




  Soft tissue sarcoma 
  Bone sarcoma 
104 
   83 (I), 79 (II) 
   21 (I), 19 (II) 
FF Finland, PH  
Gastrointestinal stromal tumor 12 (I) FFPE Finland, CFCH  
Uterine leiomyoma  
  Conventional 
  Cellular 
  With bizarre nuclei (Atypical) 
  Mitotically active 
  From HLRCC patients 
  From South African patients 
353 
   73(II),66 (III) 
   49 (II) 
   15 (II) 
   15 (II) 
   34 (II),122 (III) 
   13 (II) 
FF / FFPE 
Finland, HUCH 





(Mäkinen et al., 
2011a; Mäkinen 
et al., 2011b; 
Mäkinen et al., 
2013) 
Extrauterine leiomyoma 42 (I), 39 (II) FFPE Finland, PH/CFCH 
(Kiuru et al., 
2002) 
Endometrial polyp 54 (I), 55 (II) FFPE Finland, PH  
Lipoma 35 (I) FFPE Finland, CFCH  
Estrogen-progesterone dependent tumors 
Ovarian carcinoma 
  Clear cell 
  Serous 
  Mucinous 
  Endometrioid 
  NOS 
122 (I) 
   39 
   44  
   10 
   10 
   19 
FF / FFPE Finland, PH  
Breast cancer 
  Ductal 
  Lobular 
  Medullary 
  Other 
94 (I) 
   68 
   14 
   4 
   8 
FF Finland, OGH/PH  
Hematological malignancies 
Acute myeloid leukemia 131 (I) Fresh / FF 
Denmark, 
AAUH / US, 
MSKCC 
 
Acute lymphoblastic leukemia  




  Polycythemia vera 
  Essential   thrombocytosis 
96 (I) 
  48 
  48 
Fresh / FF US, MSKCC  
Chronic lymphocytic leukemia 746 (IV) 
  278 
  292 










(Rassenti et al., 
2004; Rassenti 
et al., 2008) 
Tumors with aberrant Wnt-signaling 
Colorectal cancer 392 (I), 183 (II) FF Finland, FCH 
(Aaltonen et al., 
1998; Salovaara 
et al., 2000) 
FFPE, formalin-fixed paraffin-embedded; FF, frozen while fresh; PH, Department of Pathology at Helsinki 
University Central Hospital; CFCH, Central Finland Central Hospital; HLRCC, Hereditary Leiomyomatosis and 
Renal Cell Cancer; HUCH, Helsinki University Central Hospital; UCT, Department of Obstetrics and Gynecology 
at University of Cape Town; NOS, not otherwise specified; OGH, Department of Obstetrics and Gynecology at 
Helsinki University Central Hospital; AAUH, Department of Hematology at Aarhus University Hospital; MSKCC, 
Memorial Sloan-Kettering Cancer Center; CRC, Chronic lymphocytic leukemia Research Consortium; OSU, Ohio 
State University Sample Bank 
Table 1. Tumor samples included in MED12 exon 1/2 mutation screenings in Studies I-IV. 
 




No. of family 
members included 
in the study 
No. of tumor 
samples included 
in the study 
Germline FH mutation Reference 
B 3 19 c.671_672delAG; p.E224fs 
(Launonen et 
al., 2001) 
C 3 5 c.1027C>T; p.R343X 
(Kiuru et al., 
2001) 
D 2 19 c.587A>G; p.H196R 
(Lehtonen et 
al., 2006) 
E 1 6 c.587A>G; p.H196R 
(Lehtonen et 
al., 2006) 
M 9 23 c.671_672delAG; p.E224fs 
(Launonen et 
al., 2001) 
N 1 6 c.1027C>T; p.R343X (Koski, 2010) 
KH-80 1 5 c.587A>G; p.H196R  
MG_56 2 12 c.671_672delAG; p.E224fs  
OuluM1 3 6 c.583A>G; p.M195V 
(Tolvanen et 
al., 2012) 
My5006 1 15 c.583A>C, p.M195V 
(Heinonen et 
al., 2014) 
My31 1 6* c.1439C>G, p.S480X 
(Mäkinen et 
al., 2014b) 
HLRCC, Hereditary Leiomyomatosis and Renal Cell Cancer; fs, frameshift; *additional 24 archival tissue 
specimens 
1.2 Normal tissue samples (I-III) 
To validate the somatic origin of the mutations observed in the first screenings, the 
genomic site was also evaluated from the corresponding normal tissue sample of each 
patient. Normal tissue samples were analyzed from two patients with uterine 
leiomyoma and two colorectal cancer patients in Study I and from five patients with 
uterine leiomyoma in Study II. Corresponding normal myometrium specimens of the 
tumor samples included in the gene expression analyses were utilized in Studies II and 
III.  
1.3 Cell lines (II, V) 
A cell line originating from human embryonic kidney cells, HEK293T (American 
Type Culture Collection [ATCC], Manassas, VA, USA), was used to express MED12 
wild-type (WT) and mutant derivatives transiently in Study II. Flp-In 293 T-Rex cell 
line (Invitrogen, Life technologies, Carlsbad, CA, USA) containing a flippase 
recognition target site at a transcriptionally active locus was utilized to create stable 
and inducible MED12 WT and mutant expressing cell lines in Study V. The cell line 
was authenticated with the Promega GenePrint10 System (Promega, Madison, WI, 




USA) at the Genomics Unit of Technology Centre, Institute for Molecular Medicine 
Finland (FIMM), Helsinki, Finland. 
2. Methods 
2.1 Histopathological evaluation (I, III) 
Histopathological evaluation of the tumor samples was performed by the collaborating 
pathologists to confirm the diagnosis (Study I) and an adequate tumor percentage of 
the samples, and to select representative areas of the tumor tissue for tissue microarray 
(TMA; Study III). For the evaluation, 5-μm sections were cut from the FFPE blocks 
and stained with hematoxylin and eosin (HE; Table 3).  
 
In Study I, pathologist Dr. Johanna Arola evaluated and classified previously collected 
series of early-onset uterine leiomyosarcoma samples according to the new criteria 
defined by the World Health Organization (WHO) (Tavassoli and Devilee, 2003; 
Ylisaukko-oja et al., 2006). Additional unselected uterine leiomyosarcoma samples 
and soft tissue sarcoma series including two uterine leiomyosarcoma metastases were 
evaluated by pathologists Dr. Jan Böhm and Prof. Tom Böhling, respectively. 
 
In Study III, all available uterine tumor specimens from the hysterectomies performed 
on 27 Finnish HLRCC patients and 66 sporadic uterine leiomyoma samples were 
evaluated, and representative tumor areas marked by gynecological pathologist 
Dr. Ralf Bützow.  
2.2 DNA and RNA extraction (I-V) 
Genomic DNA was extracted from fresh, fresh frozen, or fixed tissue samples utilizing 
either the conventional non-enzymatic method (Miller et al., 1988; Lahiri and 
Nurnberger, 1991) (I,II,IV), the standard phenol-chloroform method (IV), or the 
commercial extraction kits FastDNA® (MP Biomedicals LLC, Solon, OH, USA; I-
III), DNeasy® Blood and Tissue (Qiagen, Hilden, Germany; I,IV,V), and MagNA Pure 
LC DNA Isolation Kit I (Roche, Basel, Switzerland; I). Proteinase K digestion 
followed by phenol-chloroform isolation or the NucleoSpin® DNA FFPE XS Kit 
(Macherey-Nagel GmbH & Co KG, Düren, Germany) were utilized to extract 
genomic DNA from FFPE tissue samples (I-III). 
 
Total RNA was extracted from fresh frozen samples using TRIzol® Reagent 
(Invitrogen) or TRI Reagent® (Molecular Research Center Incorporated, Cincinnati, 
OH) (II, III). Extracted RNA was purified with RNeasy® MinElute™ Clean Up Kit 
(Qiagen) for gene expression analysis. cDNA synthesis was performed with standard 
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methods using Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase 
enzyme and random primers (Promega). 
2.3 Sanger sequencing (I-V) 
Oligonucleotide primers used in polymerase chain reaction (PCR) were designed with 
Primer3 or Primer3Plus (Untergasser et al., 2012). PCR was performed according to 
a standard protocol, and the products were purified using ExoSAP-IT (USB 
Corporation, Cleveland, OH) or A’SAP (ArcticZymes, Tromsø, Norway). Sequencing 
was performed on an Applied Biosystems ABI3730 Automatic DNA Sequencer (Life 
technologies, Thermo Fisher Scientific, Waltham, MA, USA) at the Technology 
Center, Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland. 
Sequences were analyzed manually using FinchTV and with the Mutation Surveyor 
software (Softgenetics, State College, PA, USA). 
    2.3.1 Mutation screening and validation (I-V) 
 
MED12 exon 2 mutation screening in Study I was performed with direct Sanger 
sequencing. In Study II, the samples were similarly screened for MED12 exon 1 
mutations. Sanger sequencing of cDNA was applied to four mutation-positive uterine 
leiomyoma samples from which tumor tissue was available. Somatic status of the 
mutations observed in Studies I and II was verified by sequencing the corresponding 
normal tissue samples. Mutation screenings performed in Studies III and IV included 
sequencing of both MED12 exon 1 and 2. The sample series included fresh/fresh 
frozen/fixed and FFPE samples from which 15 and 25 ng of genomic DNA, 
respectively, was used in PCR. In Study V, both genomic DNA and cDNA from the 
T-ALL patient sample were sequenced to validate the presence and expression of the 
MED12 c.97G>T, p.E33X mutation. 
    2.3.2 Loss of heterozygosity analysis (III) 
 
LOH at the FH locus was analyzed from tumor DNA (fresh frozen samples) of the 
HLRCC patient with multiple MED12 mutation-positive tumors. Five independent 
PCR reactions per sample were sequenced and the heights of the wild-type and mutant 
peaks in the chromatograms were compared manually. LOH was recorded when the 
height of the wild-type allele peak was repeatedly reduced when compared to the 




2.4 Gene expression analysis (II, III) 
Gene expression analysis to examine the global expression profiles and clustering of 
the tumors was performed utilizing Affymetrix GeneChip Human Exon 1.0 ST Arrays 
(Affymetrix, Santa Clara, CA) at the Biomedicum Functional Genomics Unit (FuGU), 
Helsinki, Finland. Re-mapped Brainarray Custom CDF files 
(HuEx10stv2_Hs_ENSG, Versions 16 and 17) were used when analyzing data with 
Partek Genomic Suite™ v. 6.5 (Partek Incorporated, St. Louis, MO, USA). All 
samples were quantile-normalized by the Robust Multichip Average (RMA) method 
and adjusted for probe sequence and GC-content. Clustering of the tumors was 
evaluated with unsupervised hierarchical clustering analysis (Cosine dissimilarity), 
performed with the most variable 1% of genes (n=372), defined by the coefficient of 
variation calculated across all tumor samples. 
2.5 Immunoprecipitation and kinase activity assay (II) 
Immunoprecipitation and kinase activity assays were performed in Prof. Thomas 
Boyer’s lab at the University of Texas, Healt Science Center at San Antonio, Texas, 
USA. MED12 exon 1 mutations were created with site-directed mutagenesis (SDM) 
to MED12 cDNA (coding for amino acids 1-593) containing pCDNA3.1 plasmids and 
further cloned to p3xFLAG-MED12 expression vectors. Plasmids were transfected to 
HEK293T cells using X-tremeGENE 9 transfection reagent (Roche), and after 48 h 
MED12 WT and mutant derivatives were immunoprecipitated from cell lysates using 
anti-FLAG M2 affinity gel (Sigma-Aldrich, St. Louis, MO). Western blot analysis of 
the immunoprecipitates was performed with antibodies designated in Table 3. [ɣ-32P]-
ATP and purified glutathione S-transferase (GST) RNA pol II CTD recombinant 
peptide were used to detect CTD-directed kinase activity of the immunoprecipitates. 
Exon 2 mutation L36R was included in the analysis as a control. 
2.6 Western blotting (II, V) 
Extracted proteins were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS PAGE) using 10% Tris-HCl polyacrylamide gels and transferred 
to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, 
CA, US). The antibodies used in protein detection are listed in Table 3. Antibody 
binding was visualized using PierceTM ECL Western Blotting Substrate (Thermo 
Fisher Scientific; II) or ChemiDocTM MP System (Bio-Rad Laboratories; V) and 
quantified with ImageQuant software (GE Healthcare, Litte Chalfont, UK).  
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2.7 Tissue microarray construction and immunohistochemistry (III) 
A manual tissue arrayer (MTA-I, Beecher Instruments, Sun Prairie, WI, USA) was 
used to construct TMAs containing 83 uterine leiomyomas from HLRCC patients and 
66 sporadic uterine leiomyomas. Four 0.8-mm tumor cores were punched from the 
representative tumor area in the original sample block and inserted into a newly casted 
paraffin block. Cores representing normal myometrium tissue were included in the 
TMAs to serve as internal controls.  
 
Immunohistochemical analysis (IHC) of FH inactivation was performed on 5-μm 
thick tissue sections of TMA or FFPE or Optimal Cutting Temperature compound 
(OCT) embedded tissue samples. The EnVisionTM + kit (Dako, Agilent Technologies, 
Santa Clara, CA) with anti-2SC antibody and anti-rabbit horseradish peroxidase 
(HRP) polymer (Table 3) was used in the analysis. The samples were scored positive 
when displaying both nuclear and cytoplasmic staining and negative when no staining 
or only low cytoplasmic staining of individual cells was observed.  
2.8 Creating MED12-expressing Flp-In 293 T-Rex cell lines (V) 
Expression vectors with MED12 mutations were created from a destination vector 
(pTO_HA_StrepIII_c_GW_FRT) containing MED12 cDNA (Varjosalo et al., 2013) 
using the QuickChange Site-Directed Mutagenesis kit (Agilent Technologies). For the 
BioID method, mutations were created in MED12 cDNA in Gateway pDONR221 
entry clones and further cloned into pTO_MYC_BirA_C vectors. Flp-In 293 T-Rex 
cells were co-transfected with the construct containing expression vectors and the Flp 
recombinase expression vector (pOG44; Invitrogen, Life Technologies) using 
FuGENE® HD Transfection Reagent (Promega). Selection with Hygromycin B 
(Invitrogen, Life Technologies) to create stable construct-expressing cell lines was 
started two days after the transfection. Stable cell lines were cultured in Dulbecco’s 
modified Eagle medium (Biowhittaker® DMEM 4.5 g/L glucose; Lonza, Basel, 
Switzerland) supplemented with 10% fetal bovine serum, 2 mM L-alanyl-L-
glutamine, 50 mg/ml penicillin, 50 mg/ml streptomycin, 15 μg/ml blasticidin, and 
100 μg/ml Hygromycin B. 
2.9 Immunofluorescence (V) 
Flp-In 293 T-Rex cells expressing HA-tagged (tag derived from human influenza 
hemagglutinin) WT or mutant MED12 derivatives were analyzed with 
immunofluorescence (IF) staining. The cells were plated on coverslips treated with 
Poly-L-lysine hydrobromide (Sigma-Aldrich) and induced to express the MED12 
construct with tetracycline (1 μg/ml Doxycycline, Sigma-Aldrich). After 24 h culture, 
cells were fixed with 4% paraformaldehyde and stained using the antibodies and dyes 




LSM 780 confocal microscope with Plan-neofluar 40x, 1.3 NA oil objective (Carl 
Zeiss, Oberkochen, Germany) were used to visualize and image the cells at the 
Biomedicum Imaging Unit, University of Helsinki, Helsinki, Finland. Two serial 
optical sections were combined and used for image display. Brightness and contrast 
was adjusted and the images were compiled with Photoshop CS5.1 (Adobe, San Jose, 
CA). 
 
The immunofluorescence images were analyzed with an Anima platform-based 
pipeline (Rantanen et al., 2014). DAPI (4’, 6-diamidino-2-phenylindole) staining was 
used to determine the areas of the cell nuclei, and the cytoplasm was defined as a 20-
pixel wide ring around each nucleus. Signal intensities of HA-tagged MED12 staining 
within the nuclei and the cytoplasms were measured, and the ratio of these intensities 




Antibody Manufacturer Method used in Study 
Primary antibodies 
Anti-FLAG M2 F3165; Sigma-Aldrich WB II 
Anti-MED23 550429; BD Biosciences WB II 
Anti-CDK19 HPA007053; Sigma-Aldrich WB II 
Anti-CDK8 sc-1521; Santa Cruz Biotechnology  WB II 
Anti-MED4 Kim et al. (Kim et al., 2006) WB II 
Anti-Cyclin C 558903; BD Biosciences WB II 
Anti-2SC Bardella et al. (Bardella et al., 2011) IHC III 
Anti-HA.11 16B12; Covance WB, IF V 
Anti-MED12 sc-5374, Santa Cruz Biotechnology WB V 
Anti-Vinculin sc-5573, Santa Cruz Biotechnology WB V 
Secondary antibodies 
Anti-mouse IgG-Peroxidase A4416; Sigma–Aldrich WB II,V 
Anti-goat IgG-Peroxidase A5420; Sigma–Aldrich WB II,V 
Anti-rabbit IgG-Peroxidase A6154; Sigma–Aldrich WB II,V 
Anti-rabbit Ig-HRP polymer Dako, Agilent Technologies IHC III 
Anti-mouse IgG-Alexa-488  R37120; Thermo Fisher Scientific IF V 
Dyes 
Hematoxylin  HE I,III 
Eosin  HE I,III 
DAB+ (3,3'-diaminobenzidine 
chromogen) 
Dako, Agilent Technologies IHC III 
F-actin probe (Phalloidin) 
conjugated  Alexa Fluor®568 
Thermo Fisher Scientific IF V 
DAPI (4’, 6-diamidino-2-
phenylindole) 
DAPI Vectashield® Mounting Media, 
Vector Laboratories  IF V 
WB, Western blotting; IHC, immunohistochemistry: IF, immunofluorescence; HE, hematoxylin and eosin staining; 
Covance, Princeton, NJ, USA; Santa Cruz Biotechnology, Santa Cruz, CA; BD Biosciences, San Diego, CA; Vector 
Laboratories, Burlingame, CA 
Table 3. Antibodies and dyes used in studies II, III, and V 
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2.10 Affinity purification and BioID -mass spectrometry (V) 
Proteome-wide protein-protein interactions were analyzed from Flp-In 293 T-Rex 
cells expressing WT or mutant MED12 derivatives with liquid chromatography-mass 
spectrometry (LC-MS/MS) preceded by single-step affinity purification (AP). The 
BioID method, based on biotinylation of the nearby proteins and subsequent mass 
spectrometry analysis, was also utilized to detect more transient interactions (Roux et 
al., 2012). Analyses were performed in collaboration with docent Markku Varjosalo 
at the Institute of Biotechnology, University of Helsinki, Helsinki, Finland. Three 
biological replicates, each consisting of tetracycline-induced cells from 5 x 15-cm 
plates, were processed for each MED12 derivative-expressing cell line. For cells 
analyzed with BioID, an additional 50 μM biotin was added 24 h prior the collection. 
A detailed description of the AP and LC-MS/MS methods can be found in the group’s 
recent publications (Varjosalo et al., 2013; Turunen et al., 2014). In brief, cells were 
lysed with HNN lysis buffer and additionally in the BioID method by sonication. The 
cleared lysates were loaded into spin columns (Bio-Rad Laboratories) with Strep-
Tactin beads (IBA GmbH, Göttingen, Germany) to isolate the Strep-tagged bait 
proteins and bound interactors. The beads were washed with HNN lysis buffer and 
with plain HNN buffer, after which the proteins were eluted with D-biotin (Thermo 
Fisher Scientific) in HNN buffer. For the LC-MS, samples were pretreated to reduce 
and alkylate the cysteine bonds and digested overnight at 37 °C with trypsin 
(Promega). Samples were further purified and re-dissolved in suitable buffers. The 
analyses were performed on an EASY-nLCII-system coupled to Orbitrap Elite ETD 
hybrid mass spectrometer using the Xcalibur version 2.2 SP 1.48 (all from Thermo 
Fisher Scientific) via a nanoelectrospray ion source as described in Varjosalo et al., 
2013. Peak extraction and subsequent protein identification against the human 
reference proteome of the UniProtKB/SwissProt database was performed utilizing the 
SEQUEST search algorithm in Proteome Discoverer software (Thermo Fisher 
Scientific). Filtering against the control contaminant database was used to identify 
high confidence protein-protein interactions. Relative protein abundances (normalized 
to the bait) were calculated from the spectral counts (average and standard deviation 
of three replicates). 
2.11 In silico prediction tools and online databases (I, IV, V) 
Functional effects of the non-synonymous changes observed in Study I were evaluated 
using the online in silico prediction tools PolyPhen2 and SIFT. Multiple Sequence 
Comparison by Log-Expectation (MUSCLE) was applied as a sequence alignment 
tool to evaluate the evolutionary conservation of the MED12 amino (N)-terminal 
region in Studies I and V. COSMIC database was utilized in Studies IV and V to 
perform a systematic search for MED12 mutations in several different cancer types 
and to analyze the presence of frame-altering or nonsense mutations in the gene. In 
Study V, four in silico prediction tools were used to evaluate the presence of a nuclear 




indicated to be lost through c.97G>T, p.E33X mutation). The UniProtKB/SwissProt 
database was utilized in peptide/protein identification after MS analyses. All in silico 
prediction tools and online databases used in this study are listed in Table 4. 
 
Application Database / Software Reference Study 
Amino acid substitution effect 
prediction 
PolyPhen2 (Adzhubei et al., 2010) I 
SIFT (Kumar et al., 2009) I 
Peptide sequence alignment MUSCLE (Edgar, 2004) I,V 
Mutation database COSMIC (Forbes et al., 2008) IV,V 
NLS prediction 
SeqNLS (Lin and Hu, 2013) V 
PSORT II (Nakai and Horton, 1999) V 
cNLS Mapper (Kosugi et al., 2009) V 
NLStradamus (Nguyen Ba et al., 2009) V 
Protein identification UniProtKB/SwissProt (UniProt Consortium, 2015) V 
2.12 Statistical analyses (II-V) 
Statistical analyses were performed with R software, version 3.0.2 (R Foundation for 
Statistical Computing, Vienna, Austria), and with Python, version 2.7 (Python 
Software Foundation, Wilmington, DE, USA). In Study II, Student’s t-test was 
utilized to evaluate the statistical significance of the differences in the levels of 32P-
GST-CTD between the MED12 WT and mutant derivative immunoprecipitates 
observed in the kinase activity assay.  
 
Fisher’s exact test (two-sided p-value) was used in Study III to test the statistical 
significance of the differences in the frequencies of MED12 mutations and biallelic 
FH inactivation between uterine leiomyomas from HLRCC patients and sporadic 
conventional uterine leiomyomas. A permutation test was utilized to evaluate the 
mutual exclusiveness of MED12 mutations and FH deficiency in uterine leiomyomas. 
Observed mutations were randomly redistributed between analyzed samples in 
1,000,000 permutations. An empirical p-value was computed as p = (1+k)/n, where k 
is the number of permutations in which at least one sample was observed with both 
changes and n is the number of permutations. To evaluate the statistical significance 
of many MED12 mutation-positive tumors co-occurring in HLRCC patient My31, 
tumors were redistributed to patients in 10,000,000 permutations. Here, k denoted the 
number of permutations in which six or more MED12 mutation-positive tumors and 
no FH-deficient tumors were distributed to the same patient. 
 
In Study IV, Fisher’s exact test was applied to evaluate the statistical significance of 
the difference observed in the accumulation of the MED12 mutations to exons 1 and 
2 between CLL and uterine leiomyomas. Associations of the MED12 mutation status 
with age, sex, the mutation status of immunoglobulin heavy chain variable (IGHV) 
genes, CD38 expression, 70 kD zeta-associated protein (ZAP-70) expression, and 
Table 4. In silico prediction tools and online databases utilized in studies I, IV, and V 
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methylation status of ZAP-70 were analyzed using Fisher’s exact test (categorical 
variables) or Wilcoxon rank sum test (continuous variables). 
 
Statistical significance of the differences in the nucleus/cytoplasm signal intensity 
ratios between cells expressing MED12 WT and mutant derivatives (G44D, E33K, 
and E33X) were evaluated using the Wilcoxon rank sum test in Study V. Student's t-
test was used to evaluate the statistical significance of the differences seen in the 
abundances of bound nuclear pore proteins between the MED12 WT and mutant 
derivatives (E33X, NLS1, and NLS2) in the BioID analysis. 
3. Ethical issues 
All samples included in the study were collected either after signed informed consent 
or after the approval by the National Supervisory Authority for Welfare and Health 
(Finland). Anonymized samples used in Studies I-III were collected after the approval 
by the director of the health care unit. Authorization to use samples of deceased 
Finnish CLL patients was obtained from the Ethics Committee of the Helsinki 
University Central Hospital. All studies were approved by the appropriate Ethics 
Committees of the Hospital District of Helsinki and Uusimaa, Finland, as well as 





1. MED12 exon 2 mutations in uterine leiomyosarcoma and 
colorectal cancer (I) 
To evaluate the role of MED12 exon 2 mutations in various tumor types other than 
uterine leiomyomas, Sanger sequencing-based mutation screening was performed on 
1158 tumor samples representing 14 different tumor types, both benign and malignant 
(see Table 1 for detailed information on the sample set). As a result, five MED12 
exon 2 mutations were identified, three in uterine leiomyosarcomas and two in 
colorectal cancers. 
1.1 MED12 exon 2 mutations occur recurrently in uterine leiomyosarcoma  
MED12 exon 2 mutations were observed in uterine leiomyosarcomas with a frequency 
of 7%, as a mutation was identified in three out of 41 samples analyzed (Table 5, 
Figure 4). Two of the mutations were observed in samples representing early onset 
(age at diagnosis ≤ 45 years) uterine leiomyosarcomas. The third was identified in a 
sample originally screened as a soft-tissue sarcoma, but further diagnosed as a uterine 
leiomyosarcoma metastasis. All three mutations occurred in the same, highly 
conserved region at the beginning of exon 2, where effectively all MED12 mutations 
are located in uterine leiomyomas. One of the mutations affected codon 44, the most 
commonly mutated codon in uterine leiomyomas, leading to a substitution of the 
glycine amino acid to serine (c.130G>A, p.G44S). Two other mutations were an 
insertion of 21 nucleotides (c.115_116ins21, p. A38_L39ins7) and a deletion of three 
nucleotides (c.104_106delAAC, p. E35_L36delinsV). Both of these changes 
represented frame-retaining insertion/deletion mutations typically seen in uterine 
leiomyomas. The somatic origin of the mutations observed in early-onset uterine 
leiomyosarcomas were verified by sequencing the DNA extracted from the 
corresponding normal tissue samples.  
1.2 Rare MED12 exon 2 mutations in colorectal cancer 
In total, 392 colorectal cancer samples were screened for MED12 exon 2 mutations. 
Only two mutations were identified (2/392; 0.5%) as a result of the screening (Table 5, 
Figure 4). One of these mutations affected the mutational hotspot codon 44. This 
mutation (c.130G>T, p.G44C) was identified in a sample from a female patient with 
a Dukes B/grade II/microsatellite stable tumor. Another missense change (c.200C>T, 
p.A67V) was observed in a sample from a female patient with a Dukes A/grade II 
tumor displaying microsatellite instability. Amino acid alanine 67 is situated at an 
evolutionary highly conserved region at the MED12 N-terminus, but no mutations 
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affecting this particular amino acid had been reported prior to this study. The 
significance of the variant remains uncertain also based on the in silico prediction tools 
PolyPhen2 and SIFT, both of which estimate A67V substitution to be tolerated. 
Corresponding normal tissue samples were sequenced, and both mutations observed 
in these colorectal cancer cases were verified as somatic.  
 
Tumor type Sample ID MED12 ex 2 mutation 
Uterine leiomyosarcoma LM_62.1T c.130G>A, p.G44S 
Uterine leiomyosarcoma LM_53.1T c.115_116ins21, p. A38_L39insSHDELTA 
Uterine leiomyosarcoma (metastasis) GE05-129 c.104_106delAAC, p.E35_L36delinsV 
Colorectal cancer c834.1T c.130G>T, p.G44C 





Figure 4. Sequence chromatograms of MED12 exon 2 mutations observed in three uterine 
leiomyosarcoma (A) and two colorectal cancer (B) samples. The mutation sites are indicated by 
arrows in the chromatograms of the tumor samples. Sequence chromatograms of the corresponding 
normal tissues are shown in the lower lanes (not available for the GE05-129 sample).   
 




2. Mutations in exon 1 of MED12 (II) 
After the identification of highly frequent MED12 mutations in uterine leiomyomas, 
subsequent Sanger sequencing-based mutation screenings had concentrated on exon 2 
and the preceding intron-exon boundary. To analyze whether mutations occur also in 
the first exon of the gene, 611 tumor samples were screened for MED12 exon 1 
mutations. The sample set represented tumor types where MED12 exon 2 mutations 
have previously been identified (uterine leiomyomas [conventional, various 
histopathological subtypes, from HLRCC patients], extrauterine leiomyomas, 
endometrial polyps, uterine leiomyosarcomas, soft-tissue and bone sarcomas, and 
colorectal cancers; see Table 1 for detailed information on the sample set). All 
individual samples included in the screening were confirmed as MED12 exon 2 
mutation-negative. 
2.1 MED12 exon 1 mutations in conventional uterine leiomyomas 
Five mutations located in exon 1 of MED12 were identified as a result of the screening 
(5/611; 0.8%). All observed mutations were in-frame insertion/deletion mutations in 
conventional uterine leiomyomas (5/86; 5.8%; Table 6). Four of the mutations were 
observed in samples from Caucasian patients and one in a uterine leiomyoma from a 
South African patient with mixed ancestry (colored) (Mäkinen et al., 2011a). The 
somatic status of all five mutations was verified through normal tissue DNA 
sequencing. Frozen specimens of the tumor tissue were available from four mutation-
positive tumors of Caucasian patients. cDNA sequencing showed predominant 
expression of the mutant allele in each tumor (Figure 1A in the original publication II). 
No mutations were observed in any other tumor type included in the screening. 
 
Ethnicity of the patient Sample ID MED12 ex 1 mutation 
Caucasian M4m2 c.76_91del16insG, p.P26_Q31delInsE 
Caucasian MY24m6 c.82_99del18, p.D28_E33del 
Caucasian MY32m13 c.82_99del18, p.D28_E33del 
Caucasian MY33m4 c.80A>T; c.84_98del15, p. Q27L; p.D28_K32del 
South African, Mixed origin FG166_1 c.77C>T; c.79_99del21, p.P26L; p.Q27_E33del 
2.2 MED12 exon 1 mutations lead to similar gene expression profile as exon 2 
      mutations 
To evaluate the functional impact of MED12 exon 1 mutations, gene expression 
analysis and immunoprecipitation accompanied with kinase activity assays were 
performed. Gene expression profiling was applied to four exon 1 mutation-positive 
tumors where RNA from the tumor tissue and corresponding normal myometrium 
Table 6.  Five MED12 exon 1 mutations observed in conventional uterine leiomyomas. 
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tissue was available. Data from these MED12 exon 1 mutation-positive tumors were 
analyzed together with the data from previous study comprising 16 MED12 exon 2 
mutation-positive tumors, four FH-deficient tumors, 10 HMGA1/HMGA2 
overexpressing tumors, and eight tumors without any of these aberrations (Mehine et 
al., 2013). All MED12 mutation-positive tumors displayed similar patterns of gene 
expression, with RAD51B being the most upregulated gene. The exact location of the 
mutation at the MED12 5’ end did not affect the clustering of the tumors as all MED12 
mutation-positive tumors clustered clearly together in unsupervised hierarchical 
clustering (Figure 5). 
Figure 5. Unsupervised hierarchical clustering analysis of 42 leiomyomas from 31 patients. Based 
on hierarchical clustering analysis, four MED12 exon 1 mutation-positive leiomyomas (black) clustered 
together with 16 MED12 exon 2 mutation-positive leiomyomas (purple). The data were analyzed 
together with data from four FH-deficient leiomyomas (red), 10 HMGA1/HMGA2 overexpressing 
leiomyomas (blue), and eight leiomyomas missing all these aberrations. 
2.3 MED12 exon 1 mutations disrupt the Mediator kinase module integrity 
Possible effects of the MED12 exon 1 mutations on the protein-protein interactions 
within Mediator were analyzed utilizing immunoprecipitation. Similarly as seen 
previously with exon 2 mutations (Turunen et al., 2014), interactions between 
Mediator kinase module components were severely disrupted. MED12 constructs 
containing exon 1 mutations (and an additional exon 2 mutant construct as a control), 
did not co-immunoprecipitate kinase module partners CDK8/19 nor Cyclin C as 
MED12 WT did (Figure 6A). Two subunits of the Mediator core, MED4 and MED23, 
were co-immunoprecipitated with all the constructs, indicating that the interaction of 
MED12 with the Mediator core remained intact despite the mutations in exons 1 and 
2 (Figure 6A). Kinase activity assays measuring the RNA-polymerase II CTD directed 




immunoprecipitates compared to that of the MED12 WT (Figure 6B). Again, an 
identical effect was observed with constructs containing MED12 exon 1 mutations as 
was seen with the exon 2 mutation-positive control and in the previous study (Turunen 




Figure 6. Immunoprecipitation followed by Western blot analysis (A) and in vitro kinase assay 
(B). MED12 derivatives harboring an exon 1 or 2 mutation loses interactions with Mediator kinase 
module components and hence the RNA pol II CTD directed kinase activity of the module. CTD-32P 
levels are expressed relative to the level in the MED12 WT immunoprcipitate (average ± SEM of three 
independent experiments). Asterisks denote statistically significant differences versus wild type, 
p < 0.001. 
3. The role of MED12 in HLRCC patients’ uterine leiomyomas 
(III) 
In Study III, the aim was to evaluate the contribution of MED12 mutations to the 
tumorigenesis of HLRCC patients’ uterine leiomyomas and to analyze whether 
MED12 mutations and the most prevalent tumorigenic mechanism in HLRCC-
associated tumors, biallelic FH inactivation, are mutually exclusive. 
3.1 MED12 mutations and FH deficiency are mutually exclusive in uterine 
      leiomyomas 
2SC immunohistochemistry, indirectly indicating FH deficiency, confirmed that the 
great majority of HLRCC patients’ uterine leiomyomas (113/122 uterine leiomyomas 
from 26 individuals; 92.6%) display biallelic inactivation of FH. Only nine tumors 
(from four different patients) showed negative 2SC staining. Interestingly, MED12 
exon 1 and 2 mutation screening revealed exon 2 mutations in all of these 2SC-
negative tumors (9/122; 7.4%; Table 7 and Figures 7 and 8). In the set of 66 sporadic 
uterine leiomyomas, 35/64 (55%) successfully sequenced tumors harbored MED12 
exon 1/2 mutation (Figure 8). All sporadic tumors were scored negative in 2SC 
immunohistochemical analysis, and were thus proficient for FH activity. The 
difference in the observed frequencies of MED12 mutations and biallelic FH 
inactivation between HLRCC patients’ and sporadic uterine leiomyomas was highly 
significant (p < 2.2x10-16). Statistical analysis of the data using a permutation test 
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(1,000,000 permutations) also validated MED12 mutations and biallelic FH 




Patient Germline FH mutation Tumors included in the screening MED12 mutation status                    2SC IHC* 
B3 c.671_672delAG, p.E224fs wt  + 
   c.131G>A, p.G44D - 
  wt  + 
B7 c.671_672delAG, p.E224fs c.113-160del48, p.A38_G53del - 
  wt + 
  wt + 
  wt + 
   wt + 
   wt + 
E1 c.587A>G, p.H196R wt + 
  wt + 
  wt + 
  wt wt 
+ 
+ 
   c.130G>A, p.G44S - 
My31 c.1439C>G, p. S480X c.130G>A, p.G44S - 
  c.131G>T, p.G44V - 
  IVS1-1_139del41 - 
  IVS1-8T>A, p.E33_D34insPQ - 
  c.131G>A, p.G44D - 
   c.130G>C, p.G44R - 
 fs, frameshift; *2SC IHC + = FH-deficient tumor; 2SC IHC - = FH-proficient tumor 
 
 





Figure 7. 2SC IHC staining of four uterine leiomyomas from two HLRCC patients (original 
magnification, x 200). FH-deficient, MED12 mutation-negative tumors display positive 2SC staining 
(left panel), whereas MED12 mutation-positive tumors are FH proficient and show negative 2SC 
staining (right panel).  
 
Figure 8. Occurrence of FH-deficient, MED12 mutation-positive, and MED12 mutation-negative 
tumors in HLRCC patients and in patients with sporadic uterine leiomyomas. The majority of the 
HLRCC patients harbored only FH-deficient tumors. Out of the four patients with at least one 
MED12 mutation-positive tumor, only one had several MED12 mutation-positive tumors. Patients with 
sporadic tumors harbored tumors with or without MED12 mutation, and no FH-deficient tumors were 
observed. 
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3.2 MED12 mutation-positive uterine leiomyomas from HLRCC patients display 
similar gene expression profile as sporadic MED12 mutation-positive tumors 
Gene expression analysis was performed to compare the expression profiles of 
HLRCC patients’ MED12 mutation-positive tumors with those of FH-deficient tumors 
and sporadic MED12 mutation-positive tumors. Data from 26 MED12 mutation-
positive tumors (seven from HLRCC patients), 10 FH-deficient, and 39 MED12 and 
FH WT tumors as well as their corresponding normal myometrial tissue samples were 
analyzed together (Mehine et al., 2013; Mehine et al., 2016). Regardless of the 
germline FH status, all tumors harboring a MED12 mutation clustered together in 
unsupervised hierarchical clustering (Figure 3 in the original publication III). FH-
deficient tumors (both from HLRCC patients and sporadic tumors with two somatic 
FH inactivating aberrations) formed their own separate cluster. Germline FH mutation 
did not affect the expression profile of the normal myometrium samples, as they all 
clustered together. 
3.3 HLRCC patient with multiple MED12 mutation-positive uterine leiomyomas 
MED12 exon 1 and 2 mutation screening combined with 2SC immunohistochemistry 
pointed out an interesting case where all tumors from one HLRCC patient (My31) 
were observed to harbor a somatic MED12 mutation and to be proficient in regard to 
FH. A different MED12 mutation was identified in all six tumors included in the 
original sample set, verifying them as separate lesions. Further analysis of 24 archival 
uterine leiomyoma tissue specimens of the patient showed all except one to be FH 
proficient and MED12 mutation-positive. Only one uterine leiomyoma sample 
displayed 2SC positivity, indicating biallelic FH inactivation, and did not harbor a 
MED12 mutation. Based on the screening results, the occurrence of this many MED12 
mutation-positive uterine leiomyomas in one HLRCC patient is highly unlikely (p = 
2x10-7, permutation test with 10,000,000 permutations). 
4. MED12 mutations in chronic lymphocytic leukemia (IV) 
A systematic database search utilizing COSMIC revealed five MED12 exon 1 or 2 
mutations in CLL. Four of these mutations occurred in exon 2, and three of them 
affected the mutational hotspots observed in uterine leiomyomas (L36 and G44). The 
fourth exon 2 mutation led to an A59P substitution. One mutation located in exon 1 
and affected the last codon of the exon coding for E33. To study the occurrence of 
MED12 mutations in CLL more thoroughly, in total 746 samples from the US and 




4.1 Somatic MED12 mutations are recurrent in CLL 
Mutation screening was performed successfully in 709 samples, and MED12 exon 1 
and 2 mutations were identified in each of the individual sample series comprising 
altogether 39 mutations in 37 samples (5.2%; Table 8). As previously, all changes 
were missense or insertion/deletion mutations retaining the reading frame. A novel 
mutation hotspot was identified as the last amino acid of exon 1, glutamic acid (E) 33, 
was the second most commonly mutated site after G44 in exon 2. Of the observed 
mutations, 27/39 (69%) situated in exon 2 and the rest (12/39; 31%) occurred in exon 1 
of the gene. The distribution between exon 1 and 2 mutations in CLL (results of this 
screening combined with the information from COSMIC) is statistically significantly 
different from the distribution observed in uterine leiomyomas (Mäkinen et al., 2011a; 
Mäkinen et al., 2011b) (p = 6.0x10-7). 
 
Sample series n* MED12 mutations  exon 1 / exon2  
Frequency of mutation-
positive samples 
In  total 746 / 709 12/25a 5.2% 
  CRC (US) 278 / 260 6 / 14a 7.7% 
  OSU Sample bank (US) 292 / 274 2 / 8 3.6% 
  HUCH (Finland) 176 / 175 4 / 3 4.0% 
CRC, Chronic lymphocytic leukemia Research Consortium; OSU, Ohio State University; HUCH, Helsinki 
University Central Hospital; *number of collected / successfully analyzed samples; atwo samples harbored two 
mutations, both in exon 2 
4.2 Positive MED12 mutation status is associated with poor prognosis markers in 
CLL 
Associations between MED12 mutation status and various molecular and clinical 
characteristics were analyzed in a CRC sample series (n=260), from which the data 
were available. A statistically significant association was observed between positive 
MED12 mutation status and unmutated IGHV status (p = 6.8x10-4), positive ZAP-70 
expression (p = 7.1x10-4), and unmethylated status of ZAP-70 (p = 5.5x10-4), all of 
which are well-established markers of poor prognosis in CLL. Despite strong 
associations, effects on overall survival or treatment-free time by the mutation status 
were not detected. Mutation status did not correlate with the age at diagnosis nor the 
gender of the patient. 
5. Somatic MED12 nonsense mutation in T-cell acute 
lymphoblastic leukemia (V) 
A MED12 nonsense mutation, c.97G>T, affecting the last codon of exon 1, E33, was 
identified in a patient with T-ALL through exome sequencing (Kontro et al., 2014). 
The mutation was validated by Sanger sequencing of the genomic DNA, and the 
Table 8. CLL samples with MED12 exon 1 and 2 mutations. 
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expression of the mutant allele was verified from the cDNA of the female patient 
(Figure 9). This mutation presumably introduces a cryptic splice site, as an additional 
low-level transcript without the last four nucleotides of exon 1 (r.96_99del) was 
observed in cDNA sequencing. To evaluate the functional effects of this atypical 
nonsense mutation, none reported in the 5’ end of MED12 previously, the translated 
protein product, its localization, and protein-protein interactions were analyzed with 
several immunochemistry and mass spectrometry-based methods. Stable and 
inducible Flp-In 293 T-Rex cell lines expressing MED12 WT and E33X mutant as 
well as E33K (CLL hotspot) and G44D (uterine leiomyoma hotspot) mutant 




Figure 9. Sequence chromatograms of the MED12 c.97G>T mutation at the genomic DNA level 
(A) and at the cDNA level (B). Wild-type reference sequences are shown in the lower lane. The mutant 
T-allele and the alternative transcript (r.96_99del) are expressed at cDNA level while the wild-type 
allele is not. 
5.1 MED12 exon 1 nonsense mutation escapes nonsense mediated mRNA decay and 
      encodes an N-terminally truncated protein 
Western blot analysis with antibody against the HA-tag in the C-terminus of each 
construct showed the MED12 derivative to be expressed from all created cell lines. 
Molecular weight of the E33X product was, however, smaller compared to other 
MED12 derivatives, and totally undetectable with the N-terminal anti-MED12 
antibody (Figure 10). Mass spectrometry-based peptide identification validated the 
observation, as no peptides originating from the N-terminus of the protein were 
identified in the E33X sample. The first MED12 peptide sequence observed in the 
E33X sample located to amino acids 163-174, and methionine (M) 154 was 
experimentally verified as the alternative start site for translation (Figure 11 and 




Figure 10. Western blot analyses of total protein isolates from 
Flp-In 293 T-Rex cells expressing MED12 WT, G44D, E33K, and 
E33X mutant derivatives. An N-terminally truncated E33X derivative 
with smaller molecular weight was detected by anti-HA antibody (A). 
Anti-MED12 antibody, whose epitope resides in the N-terminus of the 
protein (between aa25-aa75), failed to detect the E33X derivative (B). 
Vinculin was used as a loading control in both experiments. 
 
 
Figure 11. Peptide identification of MED12 WT and E33X derivative utilizing mass spectrometry. The 
most N-terminal peptide sequence identified in MED12 E33X sample located to amino acids T163-K174. 
M154 used as alternative start site for translation is marked with red box in the amino acid sequence. 
Identification of each peptide is indicated as highly confident with a <1% false discovery rate (green) or 
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5.2 MED12 E33X mutation abolishes the interactions between MED12 and other 
Mediator components  
Affinity purification and subsequent mass spectrometry demonstrated that all 
interactions between MED12 and other components of the Mediator were lost due to 
the E33X mutation. The missense mutation E33K, affecting the same amino acid, 
disrupted only the interactions between MED12 and the kinase module subunits 
CDK8/19 and Cyclin C. A similar effect with the G44D mutant derivative was 
observed previously (Turunen et al., 2014) and again in this study. No reduction in the 
interactions between MED12 and Mediator core components were observed when 
analyzing E33K and G44D missense mutants (Figure 12).  
5.3 MED12 E33X mutant derivative is missing the nuclear localization signal and 
remains in the cytoplasm 
Subcellular localization of MED12 derivatives was analyzed with 
immunofluorescence. MED12 WT and missense mutants E33K and G44D were 
localized mainly in the nucleus as expected, whereas the E33X derivative remained in 
the cytoplasm (Figure 13). Four in silico prediction tools predicted an NLS in the N-
terminus of the protein between amino acids 13-19, which are strongly evolutionarily 
conserved. To verify the existence of the NLS, two Flp-In 293 T-Rex cell lines 
expressing MED12 with modified NLS were created and further analyzed. In 
constructs NLS1 and NLS2, amino acids 13-16 PLKR and 13-19 PLKRPRL, 
respectively, were changed to stretches of alanines. Western blot analysis 
demonstrated the production of full-length MED12 from these constructs. 
Immunofluorescence analysis showing similar cytoplasmic localization as observed 
with the E33X derivative verified disabled NLS in both of the constructs (Figure 13). 
Interactions between the NLS mutant derivatives and all Mediator subunits were 







Figure 12. Protein interactions of different MED12 derivatives analyzed by AP-MS. MED12 E33X 
does not interact with any other component of the Mediator (red dots). Interactions between NLS 
mutants (purple and orange dots) and Mediator components are decreased, while the missense 
mutations G44D and E33K (light blue and dark blue dots) abolish only the interactions within the 
Mediator kinase module when compared to the WT. Error bars represent ± SD. 
 
 
Figure 13. Immunofluorescence analysis of Flp-In 293 T-Rex cells expressing MED12 WT, G44D, 
E33K, E33X, and NLS1/2 derivatives (original magnification, x 400; scale bar, 20μm). Anti-HA 
together with fluorescent dye-labeled secondary antibody and DAPI nuclear stain demonstrated the 
inaccessibility of E33X and NLS1/2 derivatives to the nuclei. 
The BioID method was used to analyze the transient protein-protein interactions of 
MED12 derivatives. Lost or strongly reduced interactions between MED12 
E33X/NLS derivatives and all other Mediator components were validated. In addition, 
analysis revealed that interactions between these derivatives and importin-α proteins 
(IMA1, IMA4, and IMA7; adaptor proteins binding to an NLS) were severely 
disrupted. Decreased interactions with the nuclear components of the nuclear pore 
HA 
DAPI 
WT MED12 G44D E33K E33X NLS1 NLS2 
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complex (NPC; NUP50, NUP153, and TPR) were also observed. Interactions between 
the corresponding cytoplasmic components of the NPC (RBP2/NUP358, NUP214, 
and NUP88) and NLS derivatives were increased (Figure 2E in the original 
publication V). These results suggest that due to the lack of intact NLS, MED12 E33X 






1. The role of MED12 in uterine leiomyomas 
1.1 MED12 mutations in uterine leiomyomas 
MED12, a subunit of the transcription regulating Mediator complex, was convincingly 
associated with human tumorigenesis when remarkably frequent mutations in the gene 
were identified in uterine leiomyomas (Mäkinen et al., 2011b). Previously, MED12 
had been connected to some cancer-related pathways, for instance canonical Wnt-
signaling and Sonic hedgehog signaling, but its role has mainly been recognized in 
various developmental processes. Several different MED12 germline mutations in the 
region coding for the LS- and PQL-domains have been established as molecular 
determinants behind X-linked intellectual disabilities, conditions such as Opitz-
Kaveggia syndrome, Lujan-Fryns syndrome, and Ohdo syndrome (MKB-type) also 
including specific physical anomalies. Recurrent somatic MED12 mutations have not 
been observed previously in any tumor type.  
 
The substantial frequency and highly specific distribution of the mutations locating to 
a narrow area of the gene provide strong evidence about the contribution of MED12 
in the tumorigenesis of uterine leiomyomas. Since the initial observation of MED12 
exon 2 mutations in uterine leiomyomas from Finnish patients, this finding has been 
repeatedly validated in several populations and ethnicities comprising Caucasian, 
African, White and Black American, Asian, Hispanic, Russian, Iranian, and Chinese 
women (Table 9, Figure 14). In all of these studies, a striking distribution of the 
mutations was observed, with the vast majority of the mutations affecting codon G44, 
signifying strong positive selection. The overall MED12 mutation frequencies have 
been considerably high in all of these studies, ranging from 50 to 80% in most of them. 
The discovery of recurrent MED12 mutations in uterine leiomyomas resulted in a huge 
leap forward in the molecular research of these extremely common, yet until then very 
poorly characterized, tumors. 
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Population  Samples analyzed 





Finnish 225 159 71% (Mäkinen et al., 2011b) 
South African 28 14 50% (Mäkinen et al., 2011a) 
German 80 47 59% (Markowski et al., 2012) 
North American 148 100 68% (McGuire et al., 2012) 
Korean 67 35 52% (Je et al., 2012) 
French 9 6 67% (Perot et al., 2012) 
North American 12 9 75% (Ravegnini et al., 2013) 
Finnish 69 41 59% (Mäkinen et al., 2013) 
German 21 10 48% (Markowski et al., 2013) 
Japanese 45 36 80% (Matsubara et al., 2013) 
Dutch 19 11 56% (de Graaff et al., 2013) 
German 12 11 92% (Rieker et al., 2013) 
German 256 179 70% (Markowski et al., 2014) 
North American 28 15 54% (Schwetye et al., 2014) 
North American 177 134 76% (Bertsch et al., 2014) 
Finnish 164 137 84% (Heinonen et al., 2014) 
Chinese and North 
American 40 30 75% (Zhang et al., 2014) 
South American 143 92 64% (Halder et al., 2015) 
Russian 122 63 52% (Osinovskaya et al., 2015) 
Iranian 23 11 48% (Shahbazi et al., 2015) 
Chinese 181 95 53% (Wang et al., 2015a) 
Iranian 103 32 31% (Sadeghi et al., 2016) 
North American/ 
Austrian/ French 16 10 63% 
(Liegl-Atzwanger et al., 
2016) 
 
Highly specific mutations in MED12 represent the only recurrent somatic small-scale 
changes observed thus far in uterine leiomyomas. Whole-exome or -genome 
sequencing of MED12 mutation-negative and -positive tumors have not revealed any 
other gene to harbor recurrent somatic point mutations relevant in myomagenesis 
(Mehine et al., 2013; Mäkinen et al., 2014b). Instead, whole-genome sequencing 
revealed interconnected complex chromosomal rearrangements in part underlying the 
cytogenetic aberrations seen in uterine leiomyomas (Mehine et al., 2013). These 
events resembled chromotripsis, the drastic shattering and random reassembling of 
affected chromosomes, but mostly in a milder form (Forment et al., 2012; Mehine et 
al., 2013). These complex rearrangements affected only a subset of the tumors, the 
majority of them being MED12 mutation-negative. In general, uterine leiomyomas are 
considered as rather stable tumors. They display relatively few cytogenetic alterations 
in addition to the initial factor driving tumorigenesis when compared to the highly 
complex karyotypes of their malignant counterpart, uterine leiomyosarcoma 





(Packenham et al., 1997; Sandberg, 2005a; Sandberg, 2005b; Perot et al., 2012; 
Mehine et al., 2013; Liegl-Atzwanger et al., 2016). Multiple leiomyomas with 
different MED12 mutations, as well as tumors driven by different driver alterations, 
can co-occur in the same uterus. The synchronous occurrence of these tumors has been 
observed more often in patients with at least one MED12 mutation-positive tumor 
(McGuire et al., 2012; Heinonen et al., 2014; Osinovskaya et al., 2015). Additionally, 
association between positive MED12 mutation status and smaller tumor size has been 
shown (Mäkinen et al., 2011b; Markowski et al., 2012; de Graaff et al., 2013; 
Heinonen et al., 2014). Correlation between MED12 mutation status and various other 
clinical variables and lifestyle factors, for instance age at diagnosis or at hysterectomy, 
age at menarche, parity, infertility, smoking, or alcohol consumption have not been 
observed (Je et al., 2012; McGuire et al., 2012; de Graaff et al., 2013; Bertsch et al., 
2014; Heinonen et al., 2014; Shahbazi et al., 2015). 
1.2 Functional impact of MED12 exon 1 and 2 mutations 
Although the etiological evidence of the role of MED12 in uterine leiomyomas is 
comprehensive, the underlying molecular mechanisms by which MED12 mutations 
elicit leiomyomagenesis are as yet unclear. The functional mechanisms of MED12 
exon 2 mutations in promoting tumorigenesis have been studied in collaboration with 
the research groups of professors Jussi Taipale and Thomas Boyer. Exon 2 mutations 
affecting the three most commonly mutated amino acids, G44, L36, and Q43, were 
included in the study, and the protein-protein interactions between mutant MED12 
derivatives and other components of the Mediator, as well as those with WT MED12, 
were analyzed (Turunen et al., 2014). A comparison revealed that exon 2 mutations 
disrupt the interaction between MED12 and Cyclin C, leading to decreased association 
of MED12 with the Cyclin C-CDK8/19 complex and further to diminished Mediator-
associated kinase activity. The binding interface required for the interaction with 
Cyclin C and for the kinase activity of CDK8 was determined to the first 100 amino 
acids of MED12. In a recent study, an integrated bioinformatic approach utilizing 
various in silico prediction programs and statistical software was used to evaluate the 
pathogenity of 14 MED12 missense mutations (Banaganapalli et al., 2016). All 
mutations, including four exon 2 missense mutations affecting codons Q43 and G44, 
were evaluated to be deleterious to the MED12 protein structure and stability. Also 
this computational analysis demonstrated a decreased binding affinity between 
MED12 mutants and Cyclin C that likely prevents proper assemblage of the kinase 
module.   
 
The fact that the genomic region which is highly mutated in uterine leiomyomas spans 
from intron 1 to exon 2 prompted us to investigate whether mutations would exist also 
in the first exon of the gene. Five MED12 exon 1 mutations were identified in 
conventional uterine leiomyomas as a result of the screening (Figure 14). All changes 
were small deletions located at the end of exon 1 and retaining the reading frame. 
Mutations in exon 1 slightly increase the overall MED12 mutation frequency in uterine 
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leiomyomas and further underline the central role of MED12 in their pathogenesis. 
MED12 exon 1 mutation-positive uterine leiomyomas displayed expression profiles 
identical with exon 2 mutation-positive lesions, including the clear overexpression of 
RAD51B. This gene has been identified as the most significantly overexpressed gene 
in MED12 exon 2 mutation-positive uterine leiomyomas in our previous study 
(Mehine et al., 2013). Even though the mechanistic effect of RAD51B in 
leiomyomagenesis is still obscure, its role seems evident, as it is also the most common 
translocation partner of HMGA2-affecting translocations. The functional impact of 
MED12 exon 1 and 2 mutations was further unified as immunoprecipitation and kinase 
activity assays demonstrated a similar disruption of the MED12 Cyclin C-CDK8/19 
interaction and reduced Mediator-associated kinase activity also with MED12 exon 1 
mutant constructs. MED12 exon 1 mutations with functional effects similar to exon 2 
mutations substantiate the notion that the N-terminus of MED12 contains a domain 
which is needed for the compilation of the kinase module and furthermore for the 
activation of CDK8. The requirement of MED12 for CDK8 kinase activity has been 
demonstrated previously, and a portion of CDK8 modules is present in a Mediator-
free form in the cells (Knuesel et al., 2009b). Whether the RNA Pol II CTD is a true 
biological substrate for CDK8 phosphorylation remains elusive, and also other 
substrates, for instance NOTCH1 and STAT transcription factors, have been 
implicated for CDK8 kinase activity (Knuesel et al., 2009b; Bancerek et al., 2013; Li 
et al., 2014).  
 
All studies where MED12 expression at the mRNA level has been assessed through 
cDNA sequencing have shown predominant expression of the mutant allele (Mäkinen 
et al., 2011b; Markowski et al., 2012; McGuire et al., 2012; Perot et al., 2012; 
Shahbazi et al., 2015; Sadeghi et al., 2016). Immunohistochemical analysis revealed 
MED12 protein expression in all conventional uterine leiomyomas, regardless of the 
mutation status, although another study observed decreased expression associated 
with complex MED12 mutations (insertions and deletions) (Perot et al., 2012; Bertsch 
et al., 2014). Further evidence about the role of MED12 in leiomyomagenesis and its 
oncogenic nature has emerged from animal experiments. A mouse model 
conditionally expressing the most common uterine leiomyoma-associated MED12 
mutation, c.131G>A (p.G44D), in uterine mesenchymal cells was shown to develop 
leiomyoma-like lesions in the uterus (Mittal et al., 2015). The mutation was effective 
in both the Med12 WT background as well as in cells where the WT Med12 was 
conditionally knocked out. Mere conditional knock out of the WT Med12 in uterine 
mesenchymal cells did not induce uterine hyperplasia or leiomyomas, indicating 
Med12 c.131G>A as a gain-of-function mutation. 
1.3 Mutually exclusive drivers of myomagenesis  
To date, at least three distinct uterine leiomyoma subgroups with different oncogenic 
changes driving tumorigenesis have been recognized. Lesions harboring MED12 




uterine leiomyomas. The second most common driver change is chromosomal 
aberrations leading to HMGA2 overexpression, with an estimated proportion of ~10%. 
Biallelic inactivation of FH, usually associated with HLRCC syndrome, covers only 
a minor fraction of the uterine leiomyomas (Mehine et al., 2014; Markowski et al., 
2015). All subgroups display unique, highly characteristic expression profiles 
(Vanharanta et al., 2006; Hodge et al., 2012; Mehine et al., 2013; Mehine et al., 2014; 
Mehine et al., 2016), and some diverging clinical and histological features are more 
often associated with a certain subgroup. These include, for instance, a smaller average 
size of MED12 mutation-positive tumors and their tendency to be present as multiple 
lesions, as well as prominent eosinophilic nucleoli surrounded by clear haloes as a 
typical histological finding in FH-deficient uterine leiomyomas (Launonen et al., 
2001; Mäkinen et al., 2011b; Markowski et al., 2012; Sanz-Ortega et al., 2013; 
Heinonen et al., 2014; Markowski et al., 2014; Joseph et al., 2015). Alterations 
affecting the COL4A5-COL4A6 locus on the X chromosome have also been suggested 
as driver events in the tumorigenesis of sporadic uterine leiomyomas (Mehine et al., 
2013). Tumors harboring COL4A5-COL4A6 aberrations display characteristic 
expressional profiles, including clear overexpression of the IRS4 gene adjacent to 
COL4A5, and cluster together in unsupervised hierarchical clustering analysis 
(Mehine et al., 2013; Mehine et al., 2016). 
 
MED12 mutations and HMGA2 overexpression have not been observed to co-occur in 
uterine leiomyomas, although some cytogenetic aberrations, for example those 
affecting the long arm of chromosome 7 or the HMGA1 locus at chromosome 6p, have 
been identified as co-occurring secondary changes (Markowski et al., 2012; Mehine 
et al., 2013; Bertsch et al., 2014). Observation of somatic MED12 mutations instead 
of biallelic FH inactivation in individual uterine leiomyomas from HLRCC patients 
suggests that these driver alterations are also mutually exclusive in myomagenesis 
(Mäkinen et al., 2013; Heinonen et al., 2014; Mäkinen et al., 2014b). The role of 
MED12 mutations in uterine leiomyomas from HLRCC patients and the mutual 
exclusiveness of MED12 mutations and biallelic FH inactivation were 
comprehensively investigated in this study. Analysis of an extensive sample set 
containing 122 uterine leiomyomas from 27 individuals with HLRCC syndrome and 
66 conventional sporadic leiomyomas clearly demonstrated that these two driver 
events are mutually exclusive in uterine leiomyomas. MED12 mutations were 
observed in 7% (9/122) of HLRCC patients’ uterine leiomyomas, and none of these 
displayed biallelic FH inactivation. In expression profiling, these tumors clustered 
together with sporadic MED12 mutation-positive lesions instead of FH-deficient 
HLRCC syndrome-associated tumors. Germline FH mutation did not affect the 
expression profiles nor alter the clustering of the normal myometrium tissue samples 
obtained from HLRCC patients. These findings confirm the presumption that given 
the high frequency of sporadic uterine leiomyomas in general, and furthermore the 
proportion of MED12 driven lesions among these, some would occur also in women 
with HLRCC syndrome. The proportion of HLRCC patients’ lesions harboring 
MED12 mutation was, however, surprisingly high in the sample set. This was due to 
a patient with six MED12 mutation-positive lesions yet carrying a germline mutation 
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in FH. Further analysis of archival tumor specimens from the patient (24 FFPE 
specimens from previous myomectomies and from other tumors removed at the 
hysterectomy), revealed only one FH-deficient HLRCC-associated tumor among 
numerous sporadic MED12 mutation-positive leiomyomas. This observed distribution 
of syndrome-associated and sporadic uterine leiomyomas in a single HLRCC patient 
is extremely unlikely, and implies the presence of an additional genetic factor that 
either protects from biallelic FH inactivation or predisposes the tissue for somatic 
MED12 mutations. All sporadic uterine leiomyomas analyzed in the study were FH-
proficient, which is in keeping with the previously observed low frequencies of 
sporadic FH-deficient lesions (Kiuru et al., 2002; Lehtonen et al., 2004; Harrison et 
al., 2015).  
2. MED12 mutations in other solid tumors 
2.1 MED12 mutations in uterine leiomyosarcomas 
In order to investigate the possible role of MED12 in other tumors, a comprehensive 
assemblage of tumor types also originating from the mesenchymal tissue or displaying 
characteristics similar to uterine leiomyomas (uterine leiomyosarcomas and other 
sarcomas, gastrointestinal stromal tumors, extrauterine leiomyomas, endometrial 
polyps, lipomas, ovarian cancers, and breast cancers) or with a connection to MED12-
related signaling (acute myeloid leukemias, acute lymphoblastic leukemias, 
myeloproliferative neoplasms, and colorectal cancers) were collected for this study. 
The genomic region of exon 2 as well as the preceding intron-exon boundary were 
analyzed for mutations by direct Sanger sequencing. The observation of five MED12 
exon 2 mutations among the analyzed 1158 tumor samples implicates that despite its 
central contribution to the development of uterine leiomyomas, MED12 does not 
possess a major role in the tumorigenesis of the tumor types analyzed here. An 
exception to this conclusion comes in the form of uterine leiomyosarcoma, where three 
out of the five mutations, two in primary tumors and one in a metastatic lesion, were 
identified. Uterine leiomyosarcomas are malignant tumors of the myometrium with a 
high recurrence rate and strong potential for metastatic dissemination (Major et al., 
1993; Gadducci et al., 1996; Giuntoli et al., 2003). Symptoms largely resemble those 
caused by uterine leiomyomas and usually uterine leiomyosarcoma is diagnosed 
postoperatively in a pathological evaluation (Leibsohn et al., 1990; Gadducci et al., 
1996). Uterine leiomyosarcomas are relatively rare (less than 0.4 cases/100,000 
women in a year) and, similar to uterine leiomyomas, their incidence is higher among 
black women (Brooks et al., 2004; Toro et al., 2006; Koivisto-Korander et al., 2012). 
In our study, 7% of leimyosarcomas harbored MED12 mutations, all of them being 
alterations typically seen in uterine leiomyomas. This observation is in line with other 
studies reporting MED12 exon 2 mutations in uterine leiomyosarcomas with 
frequencies varying from 0 to 30% (Figure 14) (Perot et al., 2012; Je et al., 2012; de 




2013; Schwetye et al., 2014; Bertsch et al., 2014; Zhang et al., 2014; Wang et al., 
2015a). Recent WES analysis of uterine leiomyosarcomas identified MED12 
mutations at a frequency of 21%, with MED12 being the third most commonly 
mutated gene after TP53 (33%) and ATRX (26%) (Mäkinen et al., 2016). All MED12 
mutations affected mutational hotspot amino acids in exon 2, and no mutations in other 
parts of the gene were observed. 
 
Benign lesions or hyperplasia of the tissue can act as a precursor for malignant tumor 
development. This concept is well established, for instance in colorectal cancer, where 
a high proportion of malignant tumors are preceded by benign adenomatous polyps 
(Fearon and Vogelstein, 1990). The observation of uterine leiomyoma-linked MED12 
exon 2 mutations in uterine leiomyosarcomas could implicate a similar sequential 
development path from benign leiomyomas to malignant leiomyosarcoma in some 
cases. This hypothesis has been suggested previously based on a similar X-
chromosome inactivation pattern of some leiomyomas and leiomyosarcomas existing 
in the same uterus and moreover displaying a microscopically visible morphological 
transition from benign leiomyoma histology to that of malignant leiomyosarcoma 
(Zhang et al., 2006). Morphologically benign areas in uterine smooth muscle tumors 
diagnosed as leiomyosarcomas have mostly represented the histology of cellular 
leiomyomas or leiomyomas with bizarre nuclei. The innocuousness of these areas was 
also verified by immunohistochemical analysis showing leiomyoma-like expression 
profiles of p53, proliferation marker Ki-67, progesterone receptor (PR), and estrogen 
receptor (ER) (Mittal and Joutovsky, 2007; Mittal et al., 2009). In addition, in some 
uterine leiomyosarcomas with a benign component, identical MED12 mutations have 
been identified in both components, suggesting their common origin (Matsubara et al., 
2013). Based on comparative genomic hybridization (CGH) analysis, almost all 
chromosomal aberrations observed in the area resembling leiomyomas were also 
present in the representative area of the leiomyosarcoma in addition to usually 
numerous and complex leiomyosarcoma-specific rearrangements (Mittal et al., 2009). 
In another study, it was noted that uterine leiomyomas harboring near-complete loss 
of the chromosome 1 short arm are more often of a cellular histological type, and the 
expressional profile of two such tumors resembled the expressional profiles of uterine 
leiomyosarcomas (Christacos et al., 2006).  
 
Our previous analysis of histopathological uterine leiomyoma subtypes revealed 
recurrent MED12 exon 2 mutations also in these lesions, albeit with significantly 
lower frequencies. Only among mitotically active leiomyomas, the mutation 
frequency (38.5%) was close to that of conventional uterine leiomyomas. In 
leiomyomas with bizarre nuclei and in tumors of the cellular subtype, the frequencies 
were substantially lower, 17% and 9%, respectively (Mäkinen et al., 2013). 
Concordant differences in MED12 mutation frequencies have been observed in other 
studies (Perot et al., 2012; Matsubara et al., 2013; Zhang et al., 2014; Liegl-Atzwanger 
et al., 2016), whereas mutations in TP53 and PTEN deletions, frequent in uterine 
leiomyosarcomas, are also recurrently observed in uterine leiomyomas with bizarre 
nuclei and in smooth muscle tumors with uncertain malignant potential (STUMP) 
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(Zhang et al., 2014). Cytogenetic observations and similar mutation frequencies give 
additional evidence for the hypothetical continuum from a benign uterine leiomyoma 
precursor to a malignant tumor. According to current understanding, conventional 
uterine leiomyomas do not possess malignant potential, and only a minor proportion 
of the histopathological leiomyoma subtypes, supposedly the cellular subtype or 
leiomyomas with bizarre nuclei, might develop into malignant leiomyosarcoma. 
Alternatively, instead of being an initiator in the uterine leiomyosarcoma 
tumorigenesis, MED12 mutations can act upon already transformed cells by giving an 
additional growth advantage and thus leading to clonal expansion. Whereas in 
conventional uterine leiomyomas MED12 expression was verified at the protein level, 
in uterine leiomyoma variants with bizarre nuclei, STUMPs, and uterine 
leiomyosarcomas, MED12 expression was reported to be decreased or missing already 
at the mRNA level and further abolished at the protein level (Perot et al., 2012). The 
authors hypothesized that MED12 could act as a tumor suppressor with attenuated 
function in leimyomagenesis, and that complete loss of function would be involved 
with the malignant transformation. Decreased MED12 protein levels in uterine 
leiomyosarcomas were noted in a subsequent study, although another study 
demonstrated positive MED12 expression at mRNA level for the majority of uterine 
leiomyosarcomas (Markowski et al., 2013; Bertsch et al., 2014).  
 
MED12 exon 2 mutations were not seen in any other smooth muscle tumors included 
in our study. In the literature, individual MED12 exon 2 mutations have been reported 
in extrauterine leiomyomas, mainly occurring in the abdominal or peritoneal area (in 
the smooth muscle tissues deriving from the Müllerian duct), as well as in endometrial 
polyps (Markowski et al., 2012; Ravegnini et al., 2013; Markowski et al., 2013; de 
Graaff et al., 2013; Rieker et al., 2013; Schwetye et al., 2014). MED12 exon 2 
mutations have also been observed in a small proportion of STUMPs and only in one 
extrauterine leiomyosarcoma (located at the thigh/femoral bone) (Perot et al., 2012; 
Schwetye et al., 2014). MED12 exon 1 mutations were neither observed in smooth 
muscle tumors (extrauterine leiomyomas, endometrial polyps, uterine 
leiomyosarcomas) nor in other sarcomas which were included in the exon 1 mutation 
screening. 
2.2 MED12 mutations in breast tumors 
In this study, no MED12 exon 2 mutations were observed in breast and ovarian cancers 
which share the strong hormonal dependency with uterine leiomyomas. Concordantly, 
MED12 exon 2 mutations have not been reported in the literature in these tumor types, 
albeit in breast carcinomas, individual mutations are observed throughout the gene 
(COSMIC and CBioPortal databases). More recent studies have, however, revealed 
frequent MED12 exon 2 mutations in fibroadenomas and phyllodes tumors of the 
breast (Lim et al., 2014; Cani et al., 2015; Yoshida et al., 2015; Nagasawa et al., 2015; 
Pfarr et al., 2015; Piscuoglio et al., 2015; Ng et al., 2015; Mishima et al., 2015; Tan 




distribution of the mutations have been strikingly similar with those seen in the uterine 
leiomyomas, strongly suggesting common pathogenic mechanisms in these tumors. 
Of note, MED12 exon 1 mutations have not been reported in fibroepithelial tumors of 
the breast, but the majority of studies have analyzed only the second exon of MED12 
for somatic mutations. Only in a few studies (including eight samples of 
fibroadenomas and 15 samples of phyllodes tumors), next-generation sequencing 
(WES or targeted sequencing) has been performed on these samples and thus also 
exon 1 has been analyzed (Lim et al., 2014; Cani et al., 2015). Fibroepithelial tumors 
of the breast, mostly comprised by fibroadenomas and to a lesser extent by phyllodes 
tumors, are hormone-dependent tumors consisting of both stromal and epithelial 
components (Yang et al., 2014). MED12 mutations were confirmed to occur only in 
the former compartment, implicating mammary stromal cells as the origin for the 
lesions (Lim et al., 2014; Yoshida et al., 2015; Mishima et al., 2015). In addition to 
the similar mutation spectrum, expression analysis of breast fibroadenomas showed 
strong correlation between the upregulated genes in uterine leiomyomas and breast 
fibroadenomas (Mäkinen et al., 2011b; Lim et al., 2014). While fibroadenomas are 
classified as benign, phyllodes tumors can, instead, be categorized into three separate 
classes based on their histology: benign (accounting ~60% of the tumors), borderline, 
and malignant with an increasing tendency to recur (Tan et al., 2012; Yang et al., 
2014). A sliding continuum of separating characteristics can be challenging to classify, 
and transformation of fibroadenomas to malignant phyllodes tumors has been 
proposed in several studies (Noguchi et al., 1995; Kuijper et al., 2002; Hodges et al., 
2009; Abe et al., 2011). Initial studies reported high and similar mutation frequencies 
in phyllodes tumors regardless of their histological grade (Cani et al., 2015; Mishima 
et al., 2015; Yoshida et al., 2015). In some studies, especially when analyzing larger 
sample sets, an inverse correlation between MED12 exon 2 mutation frequency and 
increasing degree of malignancy has been noted (Piscuoglio et al., 2015; Pfarr et al., 
2015; Ng et al., 2015; Yoon et al., 2016). Positive MED12 mutation status of the tumor 
was associated with improved disease-free survival in patients with phyllodes tumors 
(Ng et al., 2015; Yoon et al., 2016). This observation possibly reflects the role of 
hormonal regulation in these MED12 mutation-positive tumors, as dependency on 
estrogen regulation has been observed to decrease with increasing degree of 
malignancy in phyllodes tumors (Tse et al., 2002). Additional aberrations in known 
cancer genes, for instance loss-of-function mutations in TP53 and RB1, have been 
observed in malignant phyllodes tumors and are presumably driving their malignant 
progression (Cani et al., 2015). 
2.3 MED12 mutations in other hormone-associated tumors 
MED12 mutations have also been observed in other hormone-associated tumor types, 
such as prostate cancer, endometrial cancer, and adrenocortical carcinomas (Barbieri 
et al., 2012; Uterine Corpus Endometrioid Carcinoma, TCGA, USA, import from 
ICGC: COSU419; Assie et al., 2014). In all of these phenotypes, the mutation 
frequency and the location of the mutations differ substantially from those observed 
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in uterine leiomyomas and breast fibroepithelial tumors. In prostate cancer, MED12 
mutations were initially observed with a frequency of 4.6% including the recurrent 
L1224F substitution (5/7) in exon 26 at the leucine-serine-rich LS domain (Barbieri et 
al., 2012). In addition, missense mutations leading to substitutions D727E and 
P1310Q, both residing in the same LS domain, were identified in this sample set. Some 
of the subsequent sequencing studies have validated the finding, albeit with lower 
mutation frequencies, and identified additional missense mutations (M666V, E1144Q,  
V1216L, V1220E, V1223L, R1357H, N1845T, and R1899Q) in the region (Figure 14) 
(Prostate adenocarcinoma, TCGA, US and the Canadian Prostate Cancer Genome 
Network, import from ICGC: PRAD-US and PRAD-CA; Robinson et al., 2015; 
Kämpjärvi et al., 2016). One mutation affecting G44, the most frequently affected 
amino acid in uterine leiomyomas and breast fibroepithelial tumors, was also observed 
in a sequencing study of metastatic, castration-resistant prostate cancers (Robinson et 
al., 2015). Expectedly, the functional impact of the prostate cancer-associated MED12 
mutations (D727E, L1224F, P1310Q, and R1148H analyzed in Kämpjärvi et al., 
2016) clearly differs from the effects seen with N-terminal mutations. Proteome-wide 
analysis of protein-protein interactions utilizing AP-MS revealed diminished 
connections between a mutant MED12 derivative (L1224F) and MED1, 
MED13/MED13L, MED14, MED15, MED17, and MED24. The integrity of the 
kinase module and its association with the core Mediator, as well as Mediator-
associated kinase activity, were further confirmed by immunoprecipitation and kinase 
activity assays. With prostate cancer-associated MED12 mutant derivatives, changes 
were not observed in the interaction of MED12 with Cyclin C-CDK8/CDK19 nor in 
the kinase activity. Additional divergence from the N-terminal MED12 mutations in 
uterine leiomyomas and breast fibroepithelial tumors is that in prostate tumors, 
particularly the epithelial cells instead of stromal cells, harbored the MED12 mutations 
(Barbieri et al., 2012). MED12 has been reported to be overexpressed more frequently 
in metastatic and recurrent castration-resistant prostate cancers than in androgen-
sensitive prostate cancer and benign hyperplasia of the prostate (Shaikhibrahim et al., 
2014). Based on immunohistochemical analysis, nuclear accumulation of MED12 
correlated with markers of activated transforming growth factor beta (TGF-β) 
signaling and increased cell proliferation in these more advanced prostate cancer 
tissues. 
 
In endometrioid endometrial carcinoma, the most common type of endometrial cancer, 
MED12 mutations have been reported with a frequency of 5%. The mutations were 
mostly dispersed along the amino acid sequence: E79 in exon 2, and two other amino 
acids further down in the amino acid sequence being affected twice, and R521 in exon 
11 three times (Uterine Corpus Endometrioid Carcinoma, TCGA, USA, import from 
ICGC: COSU419). In adrenocortical carcinomas, mutations were observed also with 
a 5% frequency. No amino acids were affected recurrently, but all observed mutations 
were located at the C-terminus of the protein, at or adjacent to the defined β-catenin 




2.4 MED12 mutations in colorectal cancer 
Colorectal cancer constitutes the other tumor type where MED12 exon 2 mutations 
were identified in this study. Two mutations, one affecting the most commonly 
mutated amino acid in uterine leiomyomas, G44, were observed among 392 colorectal 
cancer samples, leading to a mutation frequency of 0.5%. Mutations in the leiomyoma-
linked 5’ region of MED12 have been observed in colorectal cancer with similar 
frequencies in two contemporary studies (Je et al., 2012; Cancer Genome Atlas 
Network, 2012). Although in our study MED12 exon 1 mutations were not observed 
in colorectal cancer samples, few mutations affecting the end of exon 1 have also been 
identified in colorectal cancer (COSMIC; Cancer Genome Atlas Network, 2012) 
(Figure 14). Together, these findings suggest that MED12 might have a role, yet only 
a minor one, in the pathogenesis of colorectal cancer. Another subunit of the kinase 
module, CDK8, is involved in a substantial fraction of colorectal cancers through gene 
amplifications. Enhanced kinase activity increases β-catenin-driven transcription and 
is involved in β-catenin-mediated transformation (Firestein et al., 2008). Activation 
of Wnt/β-catenin signaling associating with mutations in CDK8 kinase module 
components has been observed also in clear cell renal cell carcinomas (Arai et al., 
2014). In addition to mutations observed in Cyclin C encoding CCNC, MED12 
harbored non-recurrent mutations in its LS-domain in ~5% of the samples. Of note, in 
uterine leiomyomas, recurrent mutations or genomic rearrangements affecting the 
other kinase module subunits (MED13, Cyclin C, and CDK8/19) have not been 
observed (Mehine et al., 2013; Mäkinen et al., 2014a; Mäkinen et al., 2014b). 
3. MED12 in hematological malignancies 
3.1 MED12 mutations in chronic lymphocytic leukemia 
Among the hematological malignancies included in Study I (AML, ALL, and 
myeloproliferative neoplasms polycythemia vera and essential thrombocytosis), no 
MED12 exon 2 mutations were observed. Mutation screening of AML and ALL 
samples and in addition samples of multiple myeloma and non-Hodgkin lymphoma 
(432 samples in total) in the study by Je and colleagues also did not reveal mutations 
in these tumor types (Je et al., 2012). A systematic database search utilizing COSMIC 
revealed, however, five MED12 mutations in CLL. Four of these mutations altered 
amino acids that are recurrently affected in uterine leiomyomas and the fifth was 
located as well in exon 2 of the gene. Screening of more than 700 CLL samples for 
MED12 exon 1 and 2 mutations in this study gave further evidence on the role of 
MED12 in CLL. Mutated samples were identified with a frequency of 5.2% (37/709) 
(Figure 14), implicating MED12 as a one of the recurrently mutated genes in CLL. 
Similar to mutations detected in female solid tumors, MED12 exon 1 and 2 mutations 
in CLL were missense and insertion/deletion mutations resulting in a substitution of a 
certain amino acid or adding or skipping of varying number of amino acid residues. 
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On the other hand, a striking difference in the distribution of mutations at exons 1 and 
2 was noted when compared to uterine leiomyomas. In CLL, one third of the mutations 
occured in exon 1, with the last amino acid of the exon, E33, as a mutational hotspot, 
while in the uterine leiomyomas analyzed in our previous studies, the great majority 
of mutations (>95%) were identified in exon 2 (Mäkinen et al., 2011a; Mäkinen et al., 
2011b; Mäkinen et al., 2013; Heinonen et al., 2014). Whereas in CLL, mutations 
affecting the E33 residue were missense mutations, in uterine leiomyomas exon 1 
mutations were deletions of variable size, three abolishing the last amino acids of the 
exon from the transcript. Although in this study MED12 exon 1 mutations were not 
observed in any other tumor type in addition to uterine leiomyomas, a few mutations 
affecting E33 have also been identified in colorectal cancer and bladder cancer 
(COSMIC; Cancer Genome Atlas Network, 2012). 
 
Prior to this finding, uterine leiomyosarcoma was the only malignant tumor type where 
MED12 exon 2 mutations were observed recurrently, making CLL the first 
extrauterine cancer with recurrent 5’ end mutations in MED12. CLL is the most 
common leukemia among the adult population in Western societies. It is more 
common among men, and indeed, CLL was the first malignancy where specific 
MED12 exon 1 and 2 mutations were identified in male patients. The disease is 
characterized by clonal expansions of mature B cells expressing CD5, CD19, and 
CD23 cell-surface molecules (Fabbri and Dalla-Favera, 2016). The clinical course and 
outcome of the disease vary from relatively indolent to aggressive and fatal. Two 
subclasses based on the somatic hypermutation status of the IGHV genes are 
distinguished in CLL, and among those, unmutated IGHV status (U-CLL) is 
associated with shorter treatment-free time and overall survival (Fais et al., 1998; 
Damle et al., 1999; Hamblin et al., 1999). Expression of ZAP-70, enhancing B-cell 
receptor signaling, as well as unmethylated state of ZAP-70 are additional well-
established markers of poor prognosis in CLL (Chen et al., 2002; Rassenti et al., 2004; 
Kipps, 2007; Rassenti et al., 2008; Claus et al., 2014). Interestingly, MED12 mutations 
observed in our screening were significantly associated with these adverse prognostic 
markers although an effect on treatment-free time or overall survival was not detected.  
 
Cytogenetic alterations affecting the entire chromosome 12 or the chromosomal 
regions 13q14, 11q22-23, and 17p13, the latter ones usually associated with 
inactivation of ATM and TP53, respectively, are typical for CLL. Large-scale 
sequencing studies have revealed the mutational burden to be lower in CLL compared 
to most solid tumors (Vogelstein et al., 2013; Fabbri and Dalla-Favera, 2016). 
Although several recurrently mutated genes have been identified in CLL, only few 
reach a frequency of 10%. In addition to ATM and TP53, the NOTCH1 transcription 
factor, and SF3B1, involved in 3’ mRNA splicing, as well as BIRC3 and MYD88 
leading to activation of NF-κB signaling when mutated, are among the most 
commonly mutated genes in CLL (Puente et al., 2011; Quesada et al., 2011; Wang et 
al., 2011a; Landau et al., 2013; Puente et al., 2015; Landau et al., 2015; Fabbri and 
Dalla-Favera, 2016; Rossi and Gaidano, 2016). Individual MED12 mutations in CLL 




direct mutation screening (Quesada et al., 2011; Wang et al., 2011a; Schuh et al., 
2012; Landau et al., 2013; Damm et al., 2014). The results of our study highlight the 
importance and utility of somatic mutation databases in identifying novel cancer genes 
or connecting known cancer genes to new phenotypes when genes are mutated only at 
a moderate frequency. Currently, MED12 is recognized as a relevant cancer gene in 
CLL and has been included in the panel for targeted sequencing of CLL genes (Guieze 
et al., 2015). In this study, sequencing of relapsed or refractory CLL identified MED12 
mutations with a frequency of 8.8%. This higher mutation frequency was in line with 
the predominant unmutated IGHV status of the samples. MED12 exon 1 and 2 
mutations have been observed also in more recent WES analyses of CLL samples 
(Landau et al., 2015; Ljungstrom et al., 2016).  
    3.1.1 Wnt signaling in uterine leiomyomas and CLL 
The observation of very specific MED12 exon 1 and 2 mutations in clearly distinct 
tumor types, solid tumors of the uterus and breast, and hematological malignancy of 
the elderly, is intriguing and calls for further investigation. Dysregulation of the 
canonical Wnt/β-catenin signaling pathway is seen in a variety of tumors and is one 
of the pathways implicated in the pathogenesis of MED12 mutation-associated tumor 
types. Constitutive activation of β-catenin in the uterine mesenchyme of mice has been 
shown to induce the formation of mesenchymal tumors which resemble human uterine 
leiomyomas (Tanwar et al., 2009). Further, Wnt/β-catenin activated transcription was 
observed to promote the proliferation of human leiomyoma side-population cells in 
co-culture with mature myometrial cells. Here, the signaling pathway was activated in 
a paracrine manner by the estrogen/progesterone dependent expression of Wnt-
signaling activators in accompanying myometrial cells (Ono et al., 2013). 
Consistently, inhibition of the Wnt/β-catenin pathway with three distinct small 
molecule inhibitors resulted in decreased proliferation in primary cultures of 
leiomyoma cells (Ono et al., 2014b). Altered Wnt signaling has been observed when 
analyzing the expression profiles of uterine leiomyomas, although in our recent study 
overexpression of pathway inhibitors was noted (Mäkinen et al., 2011b; Mehine et al., 
2016). Upregulated expression of Wnt4, a pathway activator that is involved in female 
sex development, was observed in MED12 mutation-positive uterine leiomyomas 
compared to mutation-negative leiomyomas and the myometrium (Markowski et al., 
2012). Nuclear accumulation of β-catenin as a result of the activated Wnt pathway 
was observed in 6/11 MED12 mutation-positive uterine leiomyomas, while it was 
absent in all MED12 mutation-negative tumors (de Graaff et al., 2013). In another 
study, however, no nuclear accumulation was observed in an analysis of 33 uterine 
smooth muscle tumors (leiomyomas, leiomyosarcomas and STUMPs), irrespective of 
their MED12 mutation status (Perot et al., 2012).  
 
Activation of the Wnt/β-catenin signaling pathway has also been implicated in CLL 
leukemogenesis. Several factors of the signaling pathway, including Wnt growth 
factors, frizzled receptors, and LRP co-receptors, as well as the Wnt-regulated 
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transcription factor LEF1, are overexpressed in CLL cells compared to normal B cells 
(Lu et al., 2004; Gutierrez et al., 2010; Wang et al., 2014a). Downregulation of the 
signaling pathway using either small molecule inhibitors or small interfering RNAs 
(siRNA) decreased the survival of CLL cells (Lu et al., 2004; Gutierrez et al., 2010). 
In addition, somatic mutations in Wnt pathway members are observed more often than 
expected in CLL, and some have been shown to promote cell survival through 
activation of the pathway (Wang et al., 2011b; Wang et al., 2014a).  
 
MED12 constitutes the binding interface for β-catenin in Mediator and is required for 
correct activation of the Wnt signaling pathway (Kim et al., 2006; Rocha et al., 2010). 
MED12 has also been implicated in noncanonical Wnt/PCP signaling and was shown 
to regulate the closure of the neural tube in developing mouse embryos (Rocha et al., 
2010). This pathway is also established in the pathogenesis of CLL by regulating the 
migration and invasion of B cells (Kaucka et al., 2013). Whether specific MED12 
mutations per se affect Wnt signaling in uterine leiomyomas and CLL and the detailed 
role of this aberrantly regulated pathway in these diseases remain obscure and warrant 
further investigation. 
3.2 MED12 nonsense mutation in T-cell acute lymphoblastic leukemia 
Somatic MED12 exon 1 and 2 mutations observed recurrently in uterine tumors, breast 
fibroepithelial tumors, as well as in CLL have not compromised the canonical reading 
frame of MED12. The first nonsense mutation in the region, c.97G>T, leading to a 
substitution of E33 with a premature stop codon (E33X), was observed in exome 
sequencing of a T-ALL sample (Kontro et al., 2014). Assays performed with an E33X 
mutant MED12 construct in our study showed that despite the presence of the 
nonsense mutation, the protein product was expressed. Further analysis gave evidence 
that instead of nonsense-mediated mRNA decay (NMD) due to a premature nonsense 
codon, an alternative translation initiation site is utilized to produce an N-terminally 
truncated protein. NMD is a translation-dependent process that controls mRNA 
quality by eliminating erroneous premature termination codon-containing mRNAs. 
This mechanism is also utilized to maintain cellular homeostasis by downregulating 
the expression levels of some physiological mRNAs through NMD (Kurosaki and 
Maquat, 2016). The ability to escape NMD despite nonsense mutations in early exons 
has been reported in some conditions. For instance, in β-thalassemia, nonsense 
mutations in β-globin exon 1 (at the 5’ end) are able to bypass NMD and to use M55 
as an alternative translation initiation site. The resulting N-terminally truncated 
products do not cause symptoms in heterozygous carriers, whereas NMD-escaping 
nonsense mutations at the 3’ end of the gene result in C-terminally truncated products 
that lead to a rare symptomatic heterozygous form of β-thalassemia (Neu-Yilik et al., 
2011). In the case of the MED12 exon 1 nonsense mutation, a similar mechanism is 
observed in a somatic context. In a recent study, this phenomenon was analyzed 
systematically in the TCGA tumor data and was observed to be a relatively common 




In addition to a differing N-terminal amino acid composition, the subcellular 
localization of the truncated protein was altered from the nucleus to the cytoplasm. A 
nuclear localization signal (NLS) was predicted to be localized in the lost region and 
was experimentally verified using NLS-modified constructs (Figure 14). Protein-
protein interactions between MED12 derivatives with a missing or manipulated NLS 
and other components of the Mediator, in both the kinase module and the core, were 
severely impaired. A coherent decrease in the interactions is most likely due to the 
mislocalization of the mutant proteins, although an effect as a result of a missing or 
altered binding interface at the MED12 N-terminus cannot be excluded. A nuclear 
transportation mechanism where α importins recognize the NLS and direct the protein 
to the cytoplasmic side of the nuclear pore complex (NPC), leading to NPC central 
channel entry and subsequent localization to the nucleus, is suggested by the observed 
interaction changes between MED12 derivatives and NPC components. In addition to 
the established nuclear role of MED12 as a part of the Mediator, MED12 has been 
shown to function in the cytoplasm. Via a physical interaction, cytoplasmic MED12 
negatively regulates the proper maturation of transforming growth factor beta receptor 
2 (TGF-βR2) and its expression on the cell surface (Huang et al., 2012). Loss of 
MED12 expression and subsequent activation of canonical TGF-β as well as 
MEK/ERK signaling has been shown to confer resistance against various targeted 
cancer drugs and chemotherapy in a number of cancer cells (Huang et al., 2012; 
Brunen et al., 2013). Aberrant activation of TGF-β signaling protects cells from 
chemotherapy-induced apoptosis, and both pathways induce the epithelial-to-
mesenchymal transition, promoting tumorigenesis. Interaction between MED12 and 
TGF-βR2 was not seen in our MS data, which might, however, be due to the modified 
construct or the type of cell line used in the experiments. MED12 methylation has also 
been implicated in chemotherapy response. CARM1 arginine methyltransferase was 
shown to methylate two C-terminal arginines of MED12 and thus sensitizes breast 
cancer cells to commonly used chemotherapy drugs (Wang et al., 2015b). 
 
Although the impact of MED12 nonsense mutation on the development of T-ALL 
cannot be concluded based on a single case with several other mutations in leukemia 
associated genes (NOTCH1, KRAS, SUZ12, KDM6A, and STAT5B), the production of 
an N-terminally truncated protein as a result of this highly unusual mutation suggests 
an important role for MED12 in normal cell functions. The mutation was present in 
the diagnostic sample as well as in the sample taken at the time of relapse, further 
emphasizing its relevance in disease progression. Of note, the kinase module 
components Cyclin C and CDK8/19 have been previously associated with T-ALL 
tumorigenesis. The Cyclin C-CDK8/19 complex suppresses oncogenic NOTCH1 
signaling by phosphorylation and subsequent degradation of its intracellular domain 
(ICN1) (Li et al., 2014). Deletions affecting Cyclin C, as well as mutations in the ICN1 
domain, disrupt this tumor-suppressive mechanism and are frequently seen in T-ALL. 
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Figure 14. Schematic diagram of MED12 with recurrently observed somatic mutations. Different tumor 
types where somatic MED12 mutations are observed recurrently are indicated below the protein domain 
alignment. Most somatic mutations are located at a highly conserved region consisting the end of exon 1, the 
intron-exon boundary in the first intron, as well as the beginning of exon 2. Codons and one intronic 
nucleotide representing the mutational hotspots are marked with red in the amino acid alignment. In prostate 
cancer individual mutations are also observed between amino acids M666 and R1899. An NLS was identified 
at the N-terminus of MED12 (marked above the amino acid alignment). Amino acids are colored according 
to their side-chain pKas and charge at physiological pH 7.4. Green=hydrophobic; yellow=small non-polar; 
red=negatively charged; magenta=polar; blue=positively charged. Protein domains: L=leucine-rich; 
LS=leucine-serine-rich; PQL=proline-glutamine-leucine-rich; OPA=glutamine-rich opposite paired domain. 
The relevance of MED12 mutations in hematological malignancies is emerging as 
more and more samples representing various phenotypes are being sequenced. 
Targeted sequencing of T- and NK-cell post-transplant lymphoproliferative diseases 
revealed MED12 missense mutations in three of the 18 tumors analyzed. One of the 
mutations affected L36 in exon 2, and two others in exons 11 and 18 were also 
predicted as potentially damaging (Margolskee et al., 2016). MED12 mutations have 
recently been observed also in pediatric T-ALL (Spinella et al., 2016; Liu et al., 2015, 
American Society of Hematology 57th Annual Meeting 2015, abstract #691). In 
addition, MED12 was very recently identified as an essential regulator of the 
hematopoietic stem cell homeostasis (Aranda-Orgilles et al., 2016). The protein was 
observed to localize mainly to the hematopoietic stem and progenitor cell-specific 
enhancer regions, and furthermore to colocalize with essential hematopoietic 
transcription factors such as RUNX1 and GATA2. Med12 deletion caused a decrease 
in hematopoietic stem cell expression signatures and led to a rapid bone marrow 
failure and lethality. The effect was independent from the association with the kinase 
module as MED13, Cyclin C, and CDK8 were dispensable for the maintenance of 
hematopoiesis. As MED12 function is essential for physiological hematopoiesis, it 
would seem reasonable to consider putative gain-of-function MED12 mutations 




CONCLUSIONS AND FUTURE PROSPECTS 
MED12, a subunit of the Mediator complex and an important regulator of 
transcription, was recently identified as a key driver of leiomyomagenesis, as highly 
specific missense mutations and in-frame insertions and deletions affecting exon 2 of 
the gene were observed in 70% of uterine leiomyomas. Later it was shown that these 
mutations disrupt the integrity of the Mediator kinase module and abolish its kinase 
activity. This thesis work was conducted to further characterize the role of MED12 in 
the tumorigenesis of uterine leiomyomas and to analyze its contribution to the 
development of various other human tumors. Frame-retaining deletions affecting the 
first exon of MED12 in uterine leiomyomas were identified in this study. Exon 1 
mutations had similar effects on the protein-protein interactions and the tumors’ gene 
expression profiles as was previously observed in the context of exon 2 mutations. 
These results specify the domain in MED12 which is needed for the compilation of 
the Mediator kinase module and further highlight the role of MED12 in the 
tumorigenesis of these extremely common female tumors. MED12 mutations have 
been demonstrated as mutually exclusive with chromosomal rearrangements leading 
to the overexpression of HMGA2, a driver event observed in ~10% of uterine 
leiomyomas. Here, analysis of hereditary uterine leiomyomatosis and renal cell cancer 
syndrome patients’ uterine leiomyomas clearly indicated that MED12 mutations and 
biallelic FH inactivation are also mutually exclusive as drivers of leiomyomagenesis. 
In addition to syndrome-associated FH-deficient tumors, MED12-driven sporadic 
uterine leiomyomas do infrequently occur in HLRCC patients’ uteri, whereas outside 
the context of HLRCC, tumors driven by two somatic mutations in FH are very rare.  
 
As a result of the extensive mutation screenings performed in this study, recurrent 
MED12 exon 2 mutations were identified in uterine leiomyosarcoma. This observation 
and the recently reported identification of frequent MED12 exon 2 mutations in breast 
fibroepithelial tumors emphasize the gene’s role in hormone-dependent female 
tumors. This finding also demonstrates that MED12 mutations are not restricted to 
benign tumors and gives further strength to the previously suggested possibility that 
some uterine leiomyomas act as precursors for malignant leiomyosarcomas. 
Additional work is needed to elucidate the putative association of MED12 mutations 
and hormonal regulation and to further investigate the molecular mechanisms in the 
progression of uterine leiomyosarcomas. As aggressive uterine leiomyosarcomas are 
usually diagnosed postoperatively, identification of benign uterine leiomyoma 
precursors with malignant potential, if they exist, would be highly important. In 
addition to identifying suitable molecular markers for their detection, a feasible 
sampling method is also required. Analysis of cell-free DNA from the circulating 
blood has been promising in clinical use and could be applicable also in this context.  
 
Intriguingly, CLL, the most common hematological disease of adults, was the other 
malignancy where recurrent MED12 mutations were observed in this study. Mutations 
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consisted of missense mutations and small insertions and deletions similar to those 
observed in solid female tumors, but their distribution to the site of exon 1 and exon 2 
differed significantly between the tumor types. Whether this discrepancy represents a 
true tissue-specific functional difference needs to be studied more thoroughly with cell 
type-specific experiments. Also, the observed associations between positive MED12 
mutation status and several markers of poor prognosis requires validation. Analysis of 
a larger sample material from high-risk patients could reveal differences also in 
clinical outcomes that, despite strong associations, were not observed in our study. 
 
Functional assessment of the first MED12 exon 1 nonsense mutation observed in 
T-ALL identified an NLS at the beginning of MED12 and demonstrated it to be 
required for the proper nuclear localization of the protein. The protein was expressed 
despite the mutation using an alternative translation initiation site, leading to an N-
terminally truncated product that remained in the cytoplasm. These results suggest 
cytoplasmic interactions for MED12 that are important for cell viability and highlight 
the utility of even individual mutations in studying the structure and normal functions 
of proteins.  
  
Frequent oncogenic-like mutations in MED12 pose an attractive target for the 
treatment of MED12 mutation-associated tumors in the future. More detailed 
knowledge about the exact molecular mechanisms caused by these specific mutations 
in different tissues is needed to understand the process of MED12-driven 
tumorigenesis and to identify optimal targets for treatment in a given tumor type. 
Success of such targeted treatment in the case of uterine leiomyomas might, however, 
be hampered by the synchronous occurrence of multiple tumors, possibly driven by 
different genetic aberrations, in the uterus. Advances in the molecular classification of 
uterine leiomyomas and accumulating information about their clinical features should 
enable precise characterization of individual lesions and provide tools for more 
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